



HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/))

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ First, Do No Harm!

INFO ▼

CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))

(<https://www.burzynskiclinic.com>)

STANISLAW R. BURZYNSKI MD, PHD

ABOUT STANISLAW R. BURZYNSKI MD, PHD

Dr. Burzynski, a nationally and internationally recognized physician/investigator, pioneered the use of biologically active peptides for the treatment of cancer. In 1967, at the age of 24, Dr. Burzynski graduated first in his class of 250 students from the Medical Academy in Lublin, Poland. It was at this time that he identified naturally occurring human peptides, which were deficient in cancer patients. He concluded that these peptides played a role in preventing the growth of cancer cells. In 1968, he earned a PhD degree and became one of the youngest physician/investigators in Poland to hold both a MD and PhD degree.

Between 1970 and 1977, he received funding from the National Cancer Institute (NCI) for his work as a Principal investigator and Assistant Professor at the Baylor College of Medicine in Houston, TX. During this time he authored/coauthored numerous publications, including those detailing his work on naturally occurring human peptides and their effect on cancer – some of which were co-authored by investigators associated with the M.D. Anderson Cancer Center or the Baylor College School of Medicine. In May 1977, Dr. Burzynski received a Certificate of Appreciation from the Baylor College of Medicine that acknowledged his contributions to the 'Advancement of Medical Education, Research, and Health Care'.

In 1977 the Burzynski Clinic was established in Houston, TX. Since then, more than 10,000 patients have received treatment at the clinic, including more than 2,300 cancer patients who have been treated in FDA reviewed and Institutional Review Board (IRB) approved clinical trials program of Antineoplastons, investigational agents that derived from Dr. Burzynski's early investigations of naturally occurring human peptides. Currently, new FDA-reviewed Phase II and III clinical studies utilizing Antineoplastons are awaiting funding approval prior to patient enrollment.

Dr. Burzynski has extensive experience treating cancer with combinations of targeted agents and immunotherapy, and the drug phenylbutyrate (PB), which targets multiple genetic abnormalities simultaneously.

Dr. Burzynski is the author/co-author of over 300 scientific publication/presentations. He has collaborated

with investigators at the NCI, the Medical College of Georgia, the Imperial College of Science and Technology, the University of Kurume Medical School in Japan, and the University of Turin in Italy. He is a member of several prestigious organizations, including the American Association of Cancer Research (AACR), American Society of Clinical Oncology, the Society for Neuroscience, the Society for Neuro-oncology, the Royal Medical Association (UK), and the Academy of Medical Sciences. As of June 2015, he held 245 patents in 35 countries covering his scientific inventions.



CURRICULUM VITAE

STANISLAW R. BURZYNSKI, M.D., PH.D.

ACADEMIC TRAINING, CERTIFICATION AND LICENSURE

Texas State Board of Medical Examiners

License to Practice Medicine, 1973

Baylor College of Medicine, Houston, Texas

ECFMG Certificate, 1971

Medical Academy, Lublin, Poland

M.D. with Distinction, 1967

Ph.D. (Biochemistry), 1968



**Burzynski
CLINIC**

HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/))

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ([First, Do No Harm!](https://www.burzynskiclinic.com/clinical-trials/)) CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))

(<https://www.burzynskiclinic.com>)

Visiting Professor of Neuro-Oncology, Beijing Tiantan Hospital
Beijing, Tiantan, 2012 to present

Visiting Professor, Linyi People's Hospital
Linyi City, China, 2012 to present

President, Burzynski Research Institute Inc.
Houston, TX, 1983 to present

Laboratory Director, Burzynski Clinic Laboratory
Houston, TX, 1979 to present

President, Burzynski Clinic
Houston, TX, 1977 to present

Assistant Professor, Baylor College of Medicine
Houston, Texas, 1972-1977

Research Associate, Baylor College of Medicine
Houston, Texas, 1970-1972

Intern and Resident, Medical Academy, Internship in the Departments of Surgery, Internal Medicine, Pediatrics, Obstetrics and Gynecology, and Residency in the Department of Internal Medicine
Lublin, Poland, 1967-1970

Teaching Assistant, Medical Academy, Department of General Chemistry
Lublin, Poland, 1962-1967

Research Worker, Medical Academy, Department of General Chemistry
Lublin, Poland, 1961-1962

SCIENTIFIC AND PROFESSIONAL MEMBERSHIPS

American Academy of Anti-Aging Medicine
HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/)

CLINICAL TRIALS (HTTPS://WWW.BURZYNSKICLINIC.COM/CLINICAL-TRIALS)
First Do No Harm

Science
CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

International Union of Pure and Applied
Chemistry
OUR CLINIC ▼ SERVICES ▼

New York Academy of Sciences
Parenteral Drug Association

(<https://www.burzynskiclinic.com>)

American Association for Cancer Research

American Association of Pharmaceutical
Scientists

American Chemical Society

American Diabetes Association

American Medical Association

American Society of Clinical Oncology

European Association for Neuro-Oncology

Harris County Medical Society

Society for Neuro-Oncology

Society for Neuroscience

Texas Medical Association

The Royal Society of Medicine (U.K.)

The Society of Sigma Xi

World Medical Association

World Society of Anti-Aging Medicine

RESEARCH SUPPORT

National Cancer Institute Grantee, 1974-1977

Baylor College of Medicine Grantee, 1976

West Foundation Grantee, 1975

Medical Academy (Lublin, Poland) Grantee, 1962-1967

HONORS AND AWARDS

Lifetime Achievement Award from The Truth About Cancer, Nashville, TN, December 2015


Lifetime Achievement Award from the Academy of Comprehensive Integrative Medicine, Ft. Worth, TX, March, 2012

The Linus Pauling Award, October, 2008, ACAM

The Linus Pauling Award, February, 2008, Orthomolecular Health-Medicine

The Order of Merit of the President of Poland – Officer's Cross, October, 2004

Decoration of Polish Medical Association, November, 2001

 HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC ▾ SERVICES ▾
CLINICAL TRIALS ▾ INFO ▾ CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

The Order of Reconciliation - November, 2000
(<https://www.burzynskiclinic.com>)

The Cross Virtus Nobilitat, June, 1999

The Wisdom Award of Honor, December, 1998

The Medal of the President of City of Lublin, Poland, December, 1998

The Order of Saint Stanislas- Commander's Cross with Star, December, 1997

The Lady Liberty Award, July, 1997

The Gold Medal from the American Institute of Polish Culture for outstanding achievements in the field of medicine and discovery of anti-cancer drugs antineoplastons, Miami, FL, February, 1997

The Medal "Heart for Hearts" for saving human lives, Lublin, Poland, August, 1997

The Memorial Medal of Zamoyski's Lyceum in appreciation of outstanding contribution to increase scientific ranking of the school, Lublin, Poland, November, 1997

The Heritage Award by Polish American Congress in recognition of extraordinary achievement in the research, treatment, and prevention of cancer, Chicago, IL, October, 1993.

Special Medal from the Polish government's Institute for Drug Research and Control for achievement in the field of cancer research, Bialystok, Poland, September, 1989

Honorable Membership in the Academia del Medeterraneo, Rome, Italy, 1984

Recipient of commendation for Dedicated Service and for Personal Contribution made in the Advancement of Medical Education, Research and Health Care, Baylor College of Medicine, Houston, TX, April, 1977

Recipient of Medical Doctor Diploma with Distinction, Medical Academy, Lublin, Poland, 1967

Co-winner of the prize for best paper presented at the 7th Conference of Polish Medical Student Research

Societies, Poznan, Poland, 1966.

The Hereditary Title of Count

HONORABLE BIOGRAPHY

Biography published in Marquis, Who's Who in the World, 8th through 26th editions

Biography published in Marquis, Who's Who in America, 51st through 65th editions
HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC ▾ SERVICES ▾
Biography published in Marquis, Who's Who in Science and Engineering, 2nd through 6th editions
CLINICAL TRIALS ▾ INFO ▾ CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)
(https://www.burzynskiclinic.com)

Biography published in Marquis, Who's Who in Emerging Leaders in America, 1st edition

Biography published in Marquis, Who's Who Frontiers of Science and Technology, 2nd edition

Biography published in American Men and Women of Science, 13th Edition, Jacques Catell Press

CHAIRMAN OF SCIENTIFIC SESSIONS AT INTERNATIONAL MEETINGS

Co-Chairman, BIT's 8th Annual World Congress of NeuroTalk-2017, Barcelona, Spain, 2017

Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM), Dubai, UAE, 2008

1st Anti-Aging International Symposium and Exposition, Tokyo, Japan, 2006

International Conference in Integrative Medicine, Seattle, Washington, U.S.A, 1999

Comprehensive Cancer Care I Conference, Washington, D.C., U.S.A., 1998

18th International Congress of Chemotherapy, Stockholm, Sweden, 1993

17th International Congress of Chemotherapy, Berlin, Germany, 1991

9th International Symposium on Future Trends in Chemotherapy, Geneva, Switzerland, 1990

10th Congress of the Polish Pharmacological Society, Bialystok, Poland, 1989

8th International Symposium on Future Trends in Chemotherapy, Tirrenia, Italy, 1988

10th International Congress of Pharmacology, Sydney, Australia, 1987

INVITED LECTURES (GIVEN SINCE 1988)

"Precision therapy of glioblastoma." Keynote Speaker. Presented at BIT's 8th Annual World Congress of NeuroTalk-2017, Barcelona, Spain, May 22-24, 2017.

"Cancer treatment in the Information Age. The cure is in sight." Keynote Speaker. Presented at the Truth About Cancer: A Global Quest, Nashville, TN, October 14, 2016.

“Personalized targeted cancer therapy revolution.” Keynote Speaker. Presented at the 8th Annual
Medicine and Regenerative Biomedical Technologies Expo, and the 2nd
Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China, October 26, 2013.

CLINICAL TRIALS (First, Re No Harm) CONTACT (HTTPS://WWW.BURZYSKI.CLINIC.COM/CONTACT/)

(<https://www.burzynskiclinic.com>)
Presented at the 8th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical
Technologies Expo, and the 2nd Annual Asia-Pacific Anti-Aging Medicine Summit, Beijing, China,
October 26, 2013.

“Antineoplastons, chemistry, mechanism of action, design, and criticism of clinical trials.” Keynote
Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Prospective clinical trials with antineoplastons for inoperable brain tumors in children.” Keynote
Speaker. Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Phase 2 prospective clinical trials for inoperable brain tumors in adults.” Keynote Speaker.
Presented at the Integrative Cancer Therapy – Module VI, San Diego, CA, June 6, 2013.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in
children.” Keynote Speaker. Presented at the Philippine Society of Pediatric Oncology 2012 Annual
Convention in Ilo ilo, Philippines, October 27, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Update.”
Presented at the Makati Medical Center in Manila, Philippines, October 25, 2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in
children.” Keynote Speaker. Presented at St. Lukes Medical Center in Manila, Philippines, October 24,
2012.

“Phase II prospective clinical trials with Antineoplastons for inoperable brain tumors: Studies in
adults.” Keynote Speaker. Presented at St. Lukes Medical Center in Manila, Philippines, October 24,
2012.

“Phase II clinical trials of Antineoplastons in pediatric brain tumors and adult brain tumors.” Keynote
Speaker. Presented at the “2012 Shanghai World Congress on Anti-Aging Medicine and Regenerative
Biomedical Technologies Expo (A4MC-2012),” at the Shanghai World Expo Exhibition & Convention
Center in Shanghai, China, October 18, 2012.

“The future is full of hope: Cancer treatment based on genomic testing.” Keynote Speaker. Presented
at the “Hope for the Hopeless Conference,” at the American Airlines Training & Conference Center in
Ft. Worth, TX, March 9, 2012.

“Molecular Profiling in Oncology Practice: The Results of Treatment in a Group of 1,633 Patients.”
Presented at “BIT’s 4th Annual World Cancer Congress – 2011,” Dalian, China, May 24, 2011.

“Epigenomic Approach to Cancer Treatment.” Keynote Speaker. Presented at the “45th Annual
Meeting of the American Academy of Environmental Medicine,” San Diego, CA, October 21, 2010.

“Genomic and Epigenomic Principles of Cancer Treatment.” Keynote Speaker. Presented at the “10th

Scientific Meeting of the Japanese Society of Anti-Aging Medicine,” Kyoto, Japan, June 12, 2010.



Burzynski
CLINIC

HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/)) OUR CLINIC ▾ SERVICES ▾

CLINICAL TRIALS ▾ *First, Do No Harm!* INFO CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))

(<https://www.burzynskiclinic.com>)

“Antineoplastons.” Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

“Mechanisms of Anti-Tumor Activity in Synthetic Antineoplastons.” Presented for Antineoplastons Study Group of Japan, Tokyo, Japan, May 13, 2009.

“Practical Application of Gene Silencing Theory of Aging. Life Extension in Animals and Human Clinical Trials.” Presented at the “Dubai Congress on Anti-Aging & Aesthetic Medicine (DCAAAM),” Dubai, UAE, 2008

“Antineoplastons and Targeted Gene Therapy.” Presented at the “ACAM Las Vegas,” Las Vegas, Nevada, October 15-19, 2008

“Genome, Epigenome and Aging.” Presented at the “First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“Personalized Cancer Treatment in Genomics Era.” Presented at the “First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies,” Estoril, Portugal, May 29-31, 2008

“Anti-Aging Peptides – A New Frontier in Healing.” Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“Antineoplaston Peptides in Treating Cancer.” Presented at the “2008 Orthomolecular Health-Medicine conference,” San Francisco, CA, February 2008.

“Personalized Cancer Treatment.” Presented at the “2007 Total Health and Recovery Expo” in The Woodlands, Texas, October 20, 2007

“Cancer Treatment in Genomics Era.” Hosted by the Lions Health First Foundation, at the Hilton in Las Vegas, Nevada, September 15, 2007


“The Genetic Solution for Anti-Aging.” Presented at the “Healthy Directions Conference,” hosted by Dr. Julian Whitaker at the Marriott Westchase in Houston, Texas, January 6, 2007

“The Genetic Solution for Anti-Aging.” Presented at 11th Cruising for Health and Wealth, January 2006

“New Cancer Treatments and Anti-Aging Regimens.” Presented at the “Polish Club of Leisure World,” in Laguna Woods, California, March 13, 2005

“Mechanizmy i profilaktyka genetycznego starzenia (Mechanisms and Prevention of Genetic Aging).” Presented at the “Ogolnoeuropejska Konferencja Naukowo-Szkoleniowa Polskiego Towarzystwa Neurologicznego,” in Lublin, Poland, September (wrzesień) 22-25, 2004

“Regulation of Gene Expression in Cancer and Aging.” Presented at “Innovations in

 **Burzynski** Healthcare,” in Phoenix, Arizona, September 5-7, 2003
HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC ▾ SERVICES ▾
“The Role of Antineoplastons: Effect on Genes and Protein Metabolism.” Presented at
CLINICAL TRIALS First Do No Harm! CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

“The Role of Antineoplastons in Cancer and Aging.” Presented at “Ultrasound Diagnostic School, November 15, 2002

(<https://www.burzynskiclinic.com>)

“Antineoplaston Treatment of Cancer – Results of American and Japanese Clinical Trials.” Presented at ABEIM – A Cancer Symposium, Fort Worth, Texas, 2002

“Antineoplaston Cancer Treatment – Theory and Results”; “Cancer and Aging – The Connection”;

“Controlling the Key Aging Process of Methylation and Acetylation with the New Category of Anti-Aging Compounds and Antineoplastons.” Presented at the 6th International Symposium on Anti-Aging Medicine, Costa Rica, Los Suenos, August 23-24, 2002

“Treatment and Prevention of Cancer with Antineoplastons,” Presented in Santiago, Chile, July 3, 2002

“Antineoplastons –Theory and Treatment,” Presented at Seminar for Physicians: Sanoviv, Baja California, June 13, 2002

“Treatment of Brain Tumors with Antineoplastons A10 and AS2-1.” Presented at Hyman-Newman Institute for Neurology and Neurosurgery, Beth Israel Hospital, New York, August 22, 2001

“Treatment of Brain Tumors with Antineoplastons A10 and AS2-1”, Presented at Therapeutic Good Administration (TGA) of Australia, Canberra, Australia, July 17, 2001

“Antineoplastons.” Presented at Polish Medical Association, Warsaw, Poland, November 22, 2000.

“Treatment of Cancer with Antineoplastons.” Presented at Symposium organized by People Against Cancer in Stuttgart and Munich, Germany, for General Audience, November, 1999

“Antineoplastons: A Breakthrough in Cancer Therapy.” Presented at Manila Doctors Hospital, Manila, The Philippines, November 9, 1998

“The New Breakthrough in Cancer.” Presented at Marian Cancer Foundation, Manila, The Philippines, November 6, 1998

“Antineoplastons.” Presented at “Surviving Cancer.” Westminster Central Hall, London, U.K., November 15, 1997


“Antineoplastons: Theory and Clinical Trials.” Presented at Medical Academy, Lublin, Poland, November 7, 1997

“Biochemical Defense System.” Presented at Medical Academy, Lodz, Poland, July 24, 1992

“Treatment of AIDS and HIV Infection with Antineoplastons AS2-1”. Presented at Search Alliance, Los Angeles, California, November 20, 1991

“Cancer, AIDS and the other Immune System”. Presented at Foundation for the Advancement of

Science, NY, October 26, 1991

 **Burzynski** CLINIC
HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC ▼ SERVICES ▼
“Antineoplastons A10 and AS2-1 in the Treatment of Glioblastoma Multiforme” Presented at World Research Foundation Congress, Los Angeles, California,
CLINICAL TRIALS ▼ INFO ▼ CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

(https://www.burzynskiclinic.com)
“Antineoplastons A10 and AS2-1 in the Treatment of Glioblastoma Multiforme” Presented at Polish Pharmacological Society,
Lublin, Poland, August 29, 1989

“Clinical Results of Antineoplaston Therapy.” Presented at Kurume University School of Medicine,
Kurume, Japan, April 9, 1988

“Mechanism of Action of Antineoplaston A10 and Experimental Data.” Presented at Kurume
University School of Medicine, Kurume, Japan, April 8, 1988

“Isolation, Purification and Synthesis of Antineoplastons.” Presented at Kurume University School of
Medicine, Kurume, Japan, April 8, 1988

EDITORIAL POSITIONS

Reviews on recent clinical trials, Bentham Science Publishers, Editor-In-Chief.

BOOK CHAPTERS, MONOGRAPHS AND ARTICLES BY S.R. BURZYNSKI AND ASSOCIATES

1. Burzynski, S.R., Janicki, T.J., Beenken, S. Treatment of recurrent glioblastoma multiforme (rGBM) with antineoplaston AS2-1 in combination with targeted therapy. *Cancer Clin Oncol* 2019; 8(1):1-10
2. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of Antineoplastons A10 and AS2-1 in children with brain tumors. Final report (Protocol BT-10). *J Cancer Ther* 2017; 8:173-187.
3. Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Antineoplastons A10 and AS2-1 in the treatment of children with optic pathway glioma: Final report for Protocol BT-23. *Cancer Clin Oncol* 2017; 6(1):25-35.
4. Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Primary CNS tumors and leptomeningeal, disseminated and/or multicentric disease in children treated in phase II studies with antineoplastons A10 and AS2-1. *Cancer Clin Oncol* 2016; 5(2):38-48.
5. Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in children with low-grade astrocytomas—Final report (Protocol BT-13). *J Cancer Ther* 2016; 7(12):837-850.
6. Burzynski, S.R., Janicki, T.J., Burzynski, G.S. Comprehensive genomic profiling of recurrent classic

glioblastoma in a patient surviving eleven years following antineoplaston therapy. Cancer Clin




HOME (HTTPS://WWW.BURZYNSKICLINIC.COM) OUR CLINIC SERVICES

CLINICAL TRIALS INFO CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)
6(12):1063-1074.

(<https://www.burzynskiclinic.com>)

- Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent anaplastic astrocytoma. Final report (Protocol BT-15). Cancer Clin Oncol 2015;4(2):13-23.
9. Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca, J.F. Long-term survival over 21 years and pathologically confirmed complete response in pediatric anaplastic astrocytoma: A case report. J Neurol Stroke 2015;2(6):00072.
 10. Burzynski, S.R., Burzynski, G.S., Marszalek, A., Janicki, T.J., Martinez-Canca, J.F. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma treated with antineoplastons A10 and AS2-1. J Neurol Stroke 2015;2(3):00054.
 11. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas. The report on non-diffuse intrinsic pontine glioma (Protocol BT-11). J Cancer Ther 2015;6:334-344.
 12. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with newly-diagnosed anaplastic astrocytoma. Final report (Protocol BT-08). Cancer Clin Oncol 2015;4(1):28-38.
 13. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Complete response and long-term survival (>20 years) of a child with tectal glioma: A case report. Pediatr Neurosurg 2015;50(2):99-103.
 14. Burzynski, S.R., Burzynski, G.S., Brookman, S. A case of sustained objective response of recurrent/progressive diffuse intrinsic pontine glioma with phenylbutyrate and targeted agents. J Cancer Ther 2015;6:40-44.
 15. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy with pazopanib and other agents in combination with sodium phenylbutyrate in the treatment of glioblastoma multiforme. J Cancer Ther 2014;5:1423-1437.
 16. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of targeted therapy in combination with sodium phenylbutyrate in colorectal cancer after failure of second-line therapy – A potential strategy for improved survival. J Cancer Ther 2014;5:1270-1288.
 17. Burzynski, S.R., Burzynski, G.S. Long-term progression-free survival of recurrent glioblastoma multiforme treated with a combination of targeted agents: A case report. AT-14. Neuro Oncol 2014;16(Suppl. 5):v11.
 18. Burzynski, S.R., Janicki, T.J., Marszalek, A., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in patients with brainstem gliomas final report (Protocol BT-11). AT-15. Neuro Oncol 2014;16(Suppl. 5):v11.
 19. Janicki, T.J., Burzynski, G.S., Burzynski, S.R. Long-term survival (over 15 years) of pathologically confirmed recurrent glioblastoma multiforme: A case report. AT-28. Neuro Oncol 2014;16(Suppl. 5):v14-15.
 20. Burzynski, G.S., Janicki, T.J., Marszalek, A., Burzynski, S.R. Long-term survival (>20 years) of a child

with brainstem glioma treated with antineoplastons A10 and AS2-1: A case report. PT-02. Neuro



5.

HOME (HTTPS://WWW.BURZYNSKICLINIC.COM) | OUR CLINIC | SERVICES

CLINICAL TRIALS | INFO | CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

(<https://www.burzynskiclinic.com>)

22. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Brookman, S. Preliminary findings on the use of

targeted therapy in combination with sodium phenylbutyrate in recurrent advanced pancreatic cancer – A potential strategy for improved survival. J Cancer Ther 2014;5:1072-1091.

23. Burzynski, S.R., Janicki, T.J., Burzynski, G.S. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme. Final report (Protocol BT-21). J Cancer Ther 2014;5:946-956.

24. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A., Brookman, S. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors. Final report (Protocol BT-22). J Cancer Ther 2014;5:977-988.

25. Burzynski, S.R., Burzynski, G.S., Janicki, T.J. Recurrent glioblastoma multiforme, a strategy for long-term survival. J Cancer Ther 2014;5:957-976.

26. Burzynski, S.R., Patil, S.S. The effect of antineoplastons A10 and AS2-1 and metabolites of sodium phenylbutyrate on gene expression in glioblastoma multiforme. J Cancer Ther 2014;5:929-945.

27. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with high-grade glioma. Final report (Protocol BT-06), and review of recent trials. J Cancer Ther 2014;5:565-577.

28. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. The response and survival of children with recurrent diffuse intrinsic pontine glioma based on phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Child's Nervous System 2014;30(12):2051-2061.

29. Burzynski, S.R., Janicki, T.J., Burzynski, G.S., Marszalek, A. Long-term survival (> 13 years) in a child with recurrent diffuse pontine gliosarcoma: the case report. Journal of Pediatric Hematology/Oncology 2014;36(7):e433-e439. doi: 10.1097/MPH.0000000000000020.

30. Aliev, G., Burzynski, G., Ashraf, G.M., Jabir, N.R., Cacabelos, R., Benberin, V.V., Burzynski, S.R. Implication of oxidative stress-induced oncogenic signaling pathways as a treatment strategy for neurodegeneration and cancer. Syst Biol Free Rad Antioxid 2014; 2325-2347; DOI: 10.1007/978-3-642-30018-9.

31. Burzynski, S.R., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol BT-22. CT-004. Neuro-Oncology 2014;16(Suppl. 1):i10.

32. Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report. HG-017. Neuro-Oncology 2014;16(Suppl. 1):i44.

33. Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete response and normal childhood development in medulloblastoma (PNET) without recurrence: a case report. MB-039-020. Neuro-Oncology 2014;16(Suppl. 1):i80.

34. Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. NO-020.

37. Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with recurrent diffuse pontine gliosarcoma: A case report. NO-089. Neuro-Oncology 2013;15(Suppl. 3):iii120.

38. Aliev, G., Palacios, H.H., Cacabelos, P., Cacabelos, R., Burzynski, G., Burzynski, S.R. Mitochondria specific antioxidants and their derivatives in the context of the drug development for neurodegeneration and cancer. Drug Designing 2013;2(1):103.

39. Patil, S.S., Mrowczynski, E., Grela, K., Burzynski, S.R. Phenylacetylglutamate in combination with phenylbutyrate effectively inhibits growth of brain tumor cells in vitro. Neuro-Oncology 2012;14(Suppl. 3):iii16.

40. Patil, S.S., Burzynski, S.R., Mrowczynski, E., Grela, K., Chittur, S.V. Phenylacetylglutamate and phenylacetate in combination upregulate VDUP1, cause cell cycle blockade and apoptosis in U87 glioblastoma cells. Journal of Cancer Therapy 2012;3:192-200.

41. Paleolog, J., Strachecka, A., Burzynski, S.R., Olszewski, K., Borsuk, G. The larval diet supplemented with sodium phenylacetylglutamate influences the worker cuticle proteolytic system in honeybees (*Apis mellifera*). Journal of Apicultural Science 2011;55(2):73-83.

42. Burzynski, S.R., Nagy-Kubove, E. Treatment of esthesioneuroblastoma and non-small cell lung cancer with phenylbutyrate. Journal of Cancer Therapy 2011;2:518-522.

43. Burzynski, S.R., Marquis, A., Nagy-Kubove, E., Janicki, T.J. Successful treatment of recurrent triple-negative breast cancer with combination of targeted therapies. Journal of Cancer Therapy 2011;2:372-376.

44. Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S. OT-15. Preliminary results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent mixed gliomas. Neuro-Oncology 2010;12(Suppl. 4):iv72.

45. Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with antineoplastons. Neuro-Oncology 2010;12(Suppl. 4):iv10.

46. Burzynski, S.R., Weaver, R.A., Janicki, T., E, Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas. Neuro-Oncology 2010;12(6):ii95.

47. Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells. Neuro-Oncology 2010;12(6):ii87.

48. Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Neuro-Oncology 2009;11:923.

49. Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of

antineoplastons A10 and AS2-1 in patients with brainstem glioma: Protocol BC-BT-11. Neuro-



HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC SERVICES

CLINICAL TRIALS INFO CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

51. Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume XI;2009. <https://www.burzynskiclinic.com>

52. Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Neuro-Oncology 2008;10:1148.

53. Burzynski, S., Weaver, R., Janicki, T., Szymkowski, B., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma. Neuro-Oncology 2008;10:1067.

54. Patil, S., Burzynski, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints, leading to apoptosis in human glioblastoma cells. Neuro-Oncology 2008;10:786.

55. Burzynski, S., Weaver, R., Janicki, T., Burzynski, G., Samuel, S., Szymkowski, B. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Neuro-Oncology 2008; 10:821.

56. Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report. Neuro-Oncology 2008;10:450.

57. Burzynski, S.R. The genes of life. Farmapress Publishers, 2008.

58. Burzynski, S.R. Genomic approach to cancer treatment. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume X; 2008;37-44.

59. Burzynski, S.R. Recent clinical trials in diffuse intrinsic brainstem glioma. Cancer Therapy 2007;5, 379-390.

60. Burzynski, S.R., Weaver, R., Szymkowski, B. A case report of a complete response and 20-year survival of a patient with a recurrent diffuse intrinsic brainstem anaplastic astrocytoma. Neuro-Oncology 2007;9:536.

61. Patil, S., Burzynski, S.R., Mrowczynski, E., Grela, K. Phenylacetylglutamine (PG) and phenylacetate (PN) interact additively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Neuro-Oncology 2007;9:482.

62. Burzynski, S.R. The Genetic Solution for Anti-Aging. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;63-70.


63. Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;71-78.

64. Burzynski, S.R. Genetics of Brain Aging (II). Genetic Mechanisms in Encoding and Consolidation of Memory. In: American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics, Volume IX; 2007;79-88.

65. Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplastons A10 and AS 2-1 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas. Neuro-Oncology 2007;9:206.

66. Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (5). Genes

and aging of the neurons. Geny a starzenie neuronow. Czasopismo Aptekarskie 2007; Nr 3 (159)



HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC SERVICES
CLINICAL TRIALS INFO CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

68. Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (4). Time for biology and medicine. Czynniki czasu w biologii i medycynie. Czasopismo Aptekarskie 2007; Nr 2 (158) 27-36.
69. Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (3). The medicine of aging population. Medycyna starzejącego się społeczeństwa. Czasopismo Aptekarskie 2007; Nr 1 (157) 39-48.
69. Burzynski, S.R. Targeted Therapy for Brain Tumors. Editor: Andrew V. Yang. Brain Cancer Therapy and Surgical Interventions. New York (NY); Nova Science Publishers, Inc. 2006;77-111.
70. Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (2). Epigenome and gene silencing. Epigenom i wyciszanie genow. Czasopismo Aptekarskie 2006;Nr 12 (156) 29-36.
71. Burzynski, S.R. The breakthrough in therapy and prevention in medicine of 21st century (1). The medicine of genome and epigenome. Medycyna genomu i epigenomu. Czasopismo Aptekarskie 2006;Nr 11 (155) 45-52.
72. Burzynski, S.R. Age Management Treatments Which Target Silenced Genes. Redberry GW, ed. Gene Silencing: New Research. Nova Science Publishers, Inc. 2006.
73. Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Khan, M.I., Dolgoplov, V. Treatment of multicentric brainstem gliomas with antineoplastons (ANP) A10 and AS2-1. Neuro-Oncology. 2006;10:466.
74. Burzynski, S.R., Weaver, R.A., Szymkowski, B., Janicki, T.J., Khan, M.I., Dolgoplov, V. Complete response of a diffuse intrinsic brainstem tumor and von Hippel Lindau (VHL) disease to antineoplastons A10 and AS2-1 (ANP): a case report. Neuro-Oncology. 2006;10:439.
75. Burzynski, S.R. Treatments for Astrocytic Tumors in Children: Current and Emerging Strategies. Pediatric Drugs 2006;8:167-178.
76. Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 of high grade, recurrent, and progressive brainstem glioma. Integrative Cancer Therapies 2006; 5(1):40-47.
77. Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B.G., Jurida, G.F., Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas. Neuro-Oncology 2006;10:346.
78. Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back. In: American Academy of Anti-Aging Medicine. American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006.
79. Burzynski, S.R. Master Clock of Life (I). "Junk DNA." and Promoters Regions as Major Components of the Clock. American Academy of Anti-Aging Medicine (A4M) Anti-Aging Therapeutics;Volume VIII 2006.
80. Burzynski, S. R. Gene silencing theory of aging: the clinical trial supporting the theory. Anti-Aging Therapeutics 2005;Vol VII:39-46.
81. Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Neuro-Oncology 2005;7:300.

82. Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival of patients with glioblastoma multiforme treated in phase II studies with ANP. *Neuro-Oncology* 2004;15(12):168-177. [\(https://www.burzynskiclinic.com/\)](https://www.burzynskiclinic.com/)

83. Burzynski, S.R., Weaver, R.A., Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgoplov, V. Long-term survival of high-risk pediatric patients with primitive neuroectodermal tumors treated with Antineoplastons A10 and AS2-1. *Integrative Cancer Therapies* 2005;4(1):168-177. [CONTACT \(https://www.burzynskiclinic.com/contact\)](https://www.burzynskiclinic.com/contact)

84. Burzynski, S.R. Aging: Gene silencing or gene activation? *Med Hypoth* 2005; 64, 201-208.

85. Burzynski, S.R. Mechanizmy i profilaktyka genetycznego starzenia. Mechanisms and prevention of genetic aging. *Neurologia I Psychiatria* 2004;4:1-8.

86. Burzynski, S.R., Ilkowska-Musial, E., Klimczak M.W., Musial, L. Antineoplastons In Dairy Products. *Journal of Applied Nutrition* 2004;54:1-8.

87. Burzynski, S.R., Weaver, R. Bestak, , Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgoplov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. *Neuro-Oncology* 2004;6:386.

88. Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgoplov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme. *Neuro-Oncology* 2004;6:384.

89. Burzynski, S.R., Weaver, R. Bestak, , Janicki, T., Szymkowski, B., Jurida, G., Khan, M., Dolgoplov, V. Treatment of primitive neuroectodermal tumors (PNET) with antineoplastons A10 and AS2-1 (ANP). Preliminary results of phase II studies. *Neuro-Oncology* 2004;6:428.

90. Burzynski, S.R., Weaver, R. Bestak, , Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgoplov, V. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in children with atypical teratoid/rhabdoid tumors (AT/RT) of the central nervous system. A preliminary report. *Neuro-Oncology* 2004;6:427.

91. Burzynski, S.R., Lewy, R.I., Weaver, R., Janicki, T., Jurida, G., Khan, M., Larisma, C.B., Paszkowiak, J., Szymkowski, B. Long-term survival and complete response of a patient with recurrent diffuse intrinsic brain stem glioblastoma multiforme. *Integrative Cancer Therapies* 2004;3:257-261.

92. Burzynski, S.R., Weaver, R., Lewy, R., Janicki, T. Jurida, G., Szymkowski, B., Khan, M., Bestak, M. Phase II study of antineoplaston A10 and AS2-1 in children with recurrent and progressive multicentric glioma. A Preliminary Report. *Drugs R&D* 2004;5(6):315-326.

93. Burzynski, S.R. The Present State of Antineoplaston Research. *Integrative Cancer Therapies* 2004;3:47-58.

94. Burzynski, S.R., Lewy, R.I., Weaver, R.A., Axler, M.L., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I., Bestak, M. Phase II Study of Antineoplastons A10 and AS2-1 in Patients with Recurrent Diffuse Intrinsic Brain Stem Glioma (Preliminary Report). *Drugs in R&D* 2003;4:91-101.

95. Waldbillig R, Burzynski SR. Mechanism of action, uptake, and gene array studies on the antineoplastic agent phenylacetylglutamine (PG) in human glioma cells U-87. *Neuro-Oncology* 2003;10:309.

96. Burzynski, S.R., Weaver, R.A., Bestak, M., Lewy, R.I., Janicki, T.J., Jurida, G.F., Paszkowiak, J.K., Szymkowski, B.G., Khan, M.I. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in children with recurrent and progressive multicentric glioma. A preliminary report. *Neuro-Oncology*

2003;10:358.

98. Burzynski, S.R., Axler, M.L., Lewy, R.I., Janicki, Tomasz, Ilkowska-Musial, Elwira, Baranowska, Anna. Antineoplastic Supplementation in Treatment of Cancer-Related Symptoms. Journal of Applied Nutrition 2003; 53:52-60.

99. Burzynski, S. R. Gene Silencing – A New Theory of Aging. Med Hypoth 2003; 60:578-583.

100. Burzynski, S.R. In: Clinician's Complete Reference To Complementary/Alternative Medicine, Novey, D. W. (Ed.). Mosby 2000;496-507, St.Louis, USA.

101. Burzynski, S.R. The Best of Alternative Medicine. Townsend Letter for Doctors 2000;200:32.

102. Burzynski, S.R., Conde, A.B., Peters, A., Saling B., Ellithorpe, R., Daugherty, J.P., and Nacht, C.H. A Retrospective Study of Antineoplastons A10 and AS2-1 in Primary Brain Tumors. Drug Invest 1999;18:1-10.

103. Burzynski, S.R. Efficacy of Antineoplastons A10 and AS2-1. Mayo Clin. Proc 1999;74:641-643.

104. Burzynski, S.R. Antineoplastons in the treatment of malignant brain tumors. Anti-Aging Medical Therapeutics, vol. 2. Klatz RM., Goldman R. (Ed), Health Quest Publications 1998;28-34, Marina del Rey, Ca, USA.

105. Burzynski, S.R. Antineoplastons, oncogenes and cancer. Anti-Aging Medical Therapeutics, Vol.1. Klatz RM, Goldman R. (Ed), Health Quest Publication 1997; Marina del Rey, CA, USA.

106. Burzynski, S.R. Potential of antineoplastons in diseases of old age. Drugs & Aging 1995;7:157-167.

107. Soltysiak-Pawluczuk, D., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. Cellular accumulation of antineoplaston AS2-1 in human hepatoma cells. Cancer Letters 88 (1995);88:107-112.

108. Juskiewicz, M., Chodkowska, A., Burzynski, S.R., Mlynarczyk, M., Kleinrok, Z. The influence of antineoplaston A5 on particular subtypes of central dopaminergic receptors. Drugs Exptl Clin Res 1995;21:153-156.

109. Juskiewicz, M., Chodkowska, A., Burzynski, S.R., Feldo, M., Majewska, B., Kleinrok, Z. The influence of antineoplaston A5 on the central dopaminergic structures. Drugs Exptl Clin Res 1994;20:161-167.

110. Burzynski, S.R. Immunosurveillance versus chemosurveillance. Post Nauk Med 1993;6:260-262.

111. Burzynski, S.R. Antineoplastons, An Investigational Cancer Therapy. Townsend Letter for Doctors 1993;3,150-153.

112. Burzynski, S.R. Novel differentiation inducers. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992; Munich, Germany.

113. Liao, M.C., Liao, C.P., Burzynski, S.R. Potentiation of induced terminal differentiation by phenylacetic acid and related chemicals. Internat J Exptl Clin Chemother 1992;5:9-17.

114. Liao, M.C., Luong, Y., Liao, C.P., Burzynski, S.R. Prevention of drug induced DNA hypermethylation by antineoplaston components. Internat J Exptl Clin Chemother 1992;5:19-27.

115. Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers. 1992: Munich, Germany.

116. Liao, M.C., Luong, Y., Liao, C.P., Burzynski, S.R. Prevention of drug-induced DNA hypermethylation

by antineoplastons. Recent Advances in Chemotherapy. Adam D. (Ed), Futuramed Publishers.




HOME (HTTPS://WWW.BURZYNSKICLINIC.COM) OUR CLINIC SERVICES

CLINICAL TRIALS INFO CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

(<https://www.burzynskiclinic.com>)

118. Lee, S.S., Burzynski, S.R. Phase II clinical trials of antineoplastons A10 and AS2-1 in glioblastoma multiforme. Recent Advances in Chemotherapy. Adam D. (Ed) Futuramed Publishers. 1992; Munich, Germany.
119. Lee, S.S., Burzynski, S.R. Antineoplaston A5: A growth inhibitor for malignant cells and growth stimulator for normal cells. Internat J Exptl Clin Chemother 1991;4:63-65.
119. Kampalath, B.N., Liao, M.C., Burzynski, B., Burzynski, S.R. Protective effect of antineoplaston A10 in hepatocarcinogenesis induced by aflatoxin B1. Internat J Tissue Reactions 1990;12 (suppl):43-50.
120. Liao, M.C., Lee, S.S., Burzynski, S.R. Modulation of cancer methylation complex isoenzymes as a decisive factor in the induction of terminal differentiation mediated by antineoplaston A5. Internat J Tissue Reactions 1990; 12 (suppl): 27-36.
121. Lee, S.S., Burzynski, S.R. Inducibility of HL-60 leukemic cells to undergo terminal differentiation after repeated treatment with antineoplaston A5. Internat J Exptl Clin Chemother 1990;3:125-128.
122. Lee, S.S., Burzynski, S.R. Induction of differentiation of HL-60 human promyelocytic leukemic cell by antineoplaston A5. Internat J Tissue Reactions 1990;12(suppl):37-42.
123. Liao, M.C., Ashraf, A.Q., Lee, S.S., Hendry, L.B., Burzynski, S.R. Riboflavin as a minor active anticancer component of antineoplaston A2 and A5. Internat J Tissue Reactions 1990;12:19-26.
124. Liao, M.C., Lee, S.S., Burzynski, S.R. Separation of active anticancer components of antineoplaston A2, A3, and A5. Internat J Tissue Reactions 1990; 12 (suppl): 1-17.
125. Burzynski, S.R., Kubove, E., Burzynski, B. Treatment of hormonally refractory cancer of the prostate with antineoplaston AS2-1. Drugs Exptl Clin Res 1990;16: 361-369.
126. Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Internat J Exptl Clin Chemother 1989;2:63-69.
127. Liao, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of nucleic acids: A key to the induction of terminal differentiation. Internat J Exptl Clin Chemother 1989;2:187-199.
128. Hendry, L.B., Muldoon, T.G., Burzynski, S.R. Modeling studies suggest the modified dipeptide analog phenylacetyl-amino-2, 6-piperidinedione may interact with DNA. Adv Exptl Clin Chemother. 1988; 2: 11-13.
129. Burzynski, S.R. Antineoplastons: Basic research and clinical applications. Adv Exptl Clin Chemother. 1988; 2: 1-9.
130. Burzynski, S.R. Isolation, purification and synthesis of antineoplastons. Adv Exptl Clin Chemother. 1988; 6: 1-7.
131. Liao, M.C., Lee, S.S., Burzynski, S.R. Differentiation inducing components of antineoplaston A5. Adv Exptl Clin Chemother. 1988; 6: 9-25.
132. Lee, S.S., Burzynski, S.R. Terminal differentiation of HL-60 human promyelocytic leukemia cells induced by antineoplaston A2. Adv Exptl Clin Chemother 1988;6:27-31.
133. Burzynski, S.R. Treatment of bladder cancer with antineoplaston formulations. Adv Exptl Clin Chemother. 1988. 2: 37-46.
134. Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of oral formulation of antineoplaston AS2-1. Adv Exptl Clin Chemother 1988;2:29-36.

135. Burzynski, S.R. Treatment of malignant brain tumors with antineoplastons. Adv Exptl Clin



Burzynski
CLINIC

HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/)) OUR CLINIC SERVICES
CLINICAL TRIALS INFO CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))
(<https://www.burzynskiclinic.com>)

137. Ashraf, A.Q., Burzynski, S.R. Comparative study of antineoplaston A10 levels in plasma of healthy people and cancer patients. Adv Exptl Clin Chemother 1988;6:33-39.

138. Lee, S.S., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A5. Drugs Exptl Clin Res 1987;13 (suppl 1):31-35.

139. Kampalath, B.N., Liao, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by antineoplaston A10 of benzo (a) pyrene-induced pulmonary neoplasia. Drugs Exptl Clin Res 1987;13 (suppl 1):51-55.

140. Liao, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Chemosurveillance: A novel concept of the natural defense mechanism against cancer. Drugs Exptl Clin Res 1987;13 (suppl 1):71-76.

141. Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In vitro cancer growth inhibition and animal toxicity studies of antineoplaston A3. Drugs Exptl Clin Res 1987;13 (suppl 1):13-16.

142. Khalid, M., Burzynski, S.R. N,N'-disubstituted L-isoglutamines as novel cancer chemotherapeutic agents. Drugs Exptl Clin Res 1987;13 (suppl 1):57-60.

143. Hendry, L.B., Muldoon, T.G., Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical modeling studies of the interaction of antineoplaston A10 with DNA. Drugs Exptl Clin Res 1987;13 (suppl 1):77-81.

144. Burzynski, S.R., Kubove, E. Initial clinical study with antineoplaston A2 injections in cancer patients with five years follow-up. Drugs Exptl Clin Res 1987;13 (suppl 1):1-12.

145. Burzynski, S.R., Kubove, E. Phase I clinical studies of antineoplaston A3 injections. Drugs Exptl Clin Res 1987;13 (suppl 1):17-29.

146. Burzynski, S.R., Kubove, E., Burzynski, B. Phase I clinical studies of antineoplaston A5 injections. Drugs Exptl. Clin Res 1987;13 (suppl 1):37-43.

147. Liao, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative assay of plasma and urinary peptides as an aid for the evaluation of cancer patients undergoing antineoplaston therapy. Drugs Exptl Clin Res 1987;13 (suppl 1):61-70.

148. Ashraf, A.Q., Liao, M.C., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic study of radioactive antineoplaston A10 following oral administration in rats. Drugs Exptl Clin Res 1987;13 (suppl 1):45-50.

149. Burzynski, S.R., M.O. Chronic animal toxicity studies of antineoplaston A2. Drugs Exptl Clin Res 1986;12 (suppl 1):73-75.

150. Ashraf, A.Q., Liao, M.C., Mohabbat, M.O., Burzynski, S.R. Preclinical studies of antineoplaston A10 injections. Drugs Exptl Clin Res 1986;12 (suppl 1):37-45.

151. Burzynski, S.R., Mohabbat, M.O., Lee, S.S. Preclinical studies of antineoplaston AS2-1 and antineoplaston AS2-5. Drugs Exptl Clin Res 1986;12 (suppl 1):11-16.

152. Burzynski, S.R. Antineoplaston A3. Drugs of the Future 1986;11:551-552.

153. Burzynski, S.R. Antineoplastons – History of the research (I). Drugs Exptl Clin Res 1986;12 (suppl 1):1-9.

154. Burzynski, S.R. Antineoplaston AS2-5. Annual Drug Data Report 1986;8:319.

155. Burzynski, S.R. Antineoplaston AS2-1. Annual Drug Data Report 1986;8:320.

156. Burzynski, S.R., Khalid, M. Antineoplaston AS2-5. *Drugs of the Future* 1986;11:364-365.

157. Burzynski, S.R. Antineoplaston A10 injections. *Annual Drug Data Report* 1986;8:597.

158. Burzynski, S.R. Antineoplaston A10. *Annual Drug Data Report* 1986;8:591.

159. Burzynski, S.R. Antineoplaston A2. *Annual Drug Data Report* 1986;8:504.

160. Burzynski, S.R., Khalid, M. Antineoplaston AS2-1. *Drugs of the Future* 1986; 11: 361-363.

161. Burzynski, S.R. Antineoplaston A2. *Drugs of the Future* 1986; 11: 364-365.

162. Burzynski, S.R. Antineoplaston A5. *Annual Drug Data Report* 1986;8:869.

163. Burzynski, S.R. Antineoplaston A5. *Drugs of the Future* 1986;11:824-825.

164. Burzynski, S.R. Synthetic antineoplastons and analogs. *Drugs of the Future* 1986;11: 679-688.

165. Liau, M.C., Burzynski, S.R. Altered methylation complex isoenzymes as selective targets for cancer chemotherapy. *Drugs Exptl Clin Res* 1986;12 (suppl 1):77-86.

166. Lehner, A.F., Burzynski, S.R., Hendry, L.B. 3-phenylacetyl-amino-2, 6-piperidinedione, a naturally occurring peptide analog with apparent antineoplastic activity may bind to DNA. *Drugs Exptl Clin Res* 1986;12 (suppl 1):57-72.

167. Burzynski, S.R., Kubove, E. Toxicology studies of antineoplaston A10 injections in cancer patients. *Drugs Exptl Clin Res* 1986;12 (suppl 1):47-55.

168. Burzynski, S.R. Toxicology studies of antineoplaston AS2-5 injections in cancer patients. *Drugs Exptl Clin Res* 1986;12 (suppl 1):17-24.

169. Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Toxicology studies of antineoplaston AS2-1 injections in cancer patients. *Drugs Exptl Clin Res* 1986;12 (suppl 1):25-35.

170. Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and acute animal toxicity studies of antineoplaston A2. *Future Trends in Chemotherapy* 1985;6:481-484.

171. Burzynski, S.R., Hai TT. Antineoplaston A10. *Drugs of the Future* 1985;10:103-105.

172. Burzynski, S.R. Phase I clinical studies of antineoplaston AS2-5 injections. *Recent Advances in Chemotherapy*. Ishigami J. (Ed), University of Tokyo Press. 1985; Tokyo, Japan.

173. Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. *Future Trends in Chemotherapy* 1985;6:485-493.

174. Burzynski, S.R., Mohabbat MO, Burzynski B. Animal toxicology studies on oral formulation of antineoplaston A10. *Drugs Exptl Clin Res* 1984;10:113-118.

175. Lee, S.S., Mohabbat, M.O., Burzynski, S.R. Tissue culture and animal toxicity studies of antineoplaston A2. *Drugs Exptl Clin Res* 1984;10:607-610.

176. Burzynski, S.R. Antineoplaston A10. *Annual Drug Data Report* 1984;6:124.

177. Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Human toxicology studies on oral formulation of antineoplaston A10. *Drugs Exptl Clin Res* 1984;10:891-909.

178. Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology studies on oral formulation of antineoplaston A10 in cancer patients. *Drugs Exptl Clin Res* 1984;10:611-619.

179. Beall, P., Szopa, B., Burzynski, S.R., Hazlewood, C.F. Polypeptides that inhibit human breast cancer cell division. *Cancer Biochem Biophys* 1979;3:93-96.

180. Burzynski, S.R. *Przegląd Lekarski* 1978;6:583-586.

181. Gross S, Galicka N, Grabarczyk M, Giannini M, Burzynski SR, Stolzmann Z. Urinary peptides inhibit DNA synthesis in vitro in certain cultured neoplastic cells. *Clin Chem* 1977;23:148-149.

182. Burzynski, S.R., Stolzmann, Z., Szopa, B., Stolzmann, E., Kaltenberg, O.P. Antineoplaston A in cancer

therapy (I). *Physiol Chem Phys* 1977;9:485-500.

183. Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H. Peptides: Biochemical defense against cancer. *Physiol Chem Phys* 1976;8:161-166.

184. Georgiades, J., Burzynski, S.R., Stolzmann, A. Urinary peptides in muscular dystrophy. *Physiol Chem Phys* 1976;8:161-166.

185. Burzynski, S.R. Sequential analysis of human urinary peptide; Determination of the structure of a habituation-induced brain peptide (ameletin). *Anal Biochem* 1976;70:359-365.

186. Burzynski, S.R., Loo, T.L., Ho, D.H., Rao, P.N., Georgiades, J., Kratzenstein, H. Biologically active peptides in human urine: III. Inhibitors of the growth of leukemia, osteosarcoma and HeLa cells. *Physiol Chem Phys* 1976;8:13-22.

187. Burzynski, S.R., Rao, P.N., Gross, S., Stolzmann, Z. Inhibition of the Growth of HeLa Cells by the Peptide Isolated from Normal Human Urine. *Fed Proc* 1976;35:623.

188. S.R. Quantitative analysis of amino acids and peptides in the femtomolar range. *Anal Biochem* 1975;65:93-99.

189. Burzynski, S.R., Ungar, G. Brain Peptides Associated with Habituation to a Sound Stimulus. *Neuroscience Abstracts* 1975;1:329.

190. Ungar, G., Burzynski, S.R., Tate, D.L. Learning-induced Brain Peptides. *Peptides: Chemistry, structure and biology*. Walter, R., Meienhofer, J. (Ed), Ann Arbor Science; 1975; Ann Arbor, Michigan, USA.

191. Burzynski, S.R., Ungar, A.L., Lubanski, E. Biologically active peptides in human urine: II. Effect on intestinal smooth muscle and heart. *Physiol Chem Phys* 1974;6:457-468.

192. Burzynski, S.R., Ungar, A.L., Lubanski, E. Effect of Urinary Peptides on Smooth Muscle and Heart. *Fed Proc* 1974;33:547.

193. Burzynski, S.R. Biologically active peptides in human urine: I. Isolation of a group of medium-sized peptides. *Physiol Chem Phys* 1973;5:437-447.

194. Burzynski, S.R., Georgiades, J. Effect of Urinary Peptides on DNA, RNA and Protein Synthesis in Normal and Neoplastic Cells. *Fed Proc* 1973;32:766.

195. Ungar, G., Burzynski, S.R. Isolation and Purification of a Habituation-inducing Peptide from Trained Rat Brain. *Fed Proc* 1973;32:367.

196. Burzynski, S., Czerniak, Z. A simple method for the separation of free and bound amino acids and its application to the identification of bound amino acids in human blood serum. *Chem Anal* 1970;15:223-225.

197. Szajner-Milart, J., Burzynski, S.R., Paczos-Chadyma, E., Czerniak, Z. Free amino acids in serum of obese children. *Endokr Pol* 1970;21:611-617.

198. Krzeczowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of carbohydrates and their statistical analysis, I. Results obtained in various conditions using paper and thin-layer chromatography. *Chem Anal* 1969;13:1221-1228.

199. Burzynski, S. Investigations on unknown ninhydrin-reacting substances in human blood serum I. Attempts at identification of three such substances. *Experientia* 1969;25:490-491.

200. Burzynski, S. Bound amino acids in serum of patients with chronic renal insufficiency. *Clin Chim Acta* 1969;25:231-237.


201. Czerniak, Z., Burzynski, S. Free amino acids in serum of patients with chronic renal insufficiency.

204. Czerniak, Z., Burzynski, S. Qualitative analysis of amino acids using the multiple development of chromatograms in different eluents. Chem Anal 1969;14:673-676.
205. Krzeczowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in human blood with the use of our own method and Beckman amino acid analyzer. Pol Arch Med Wewn 1968;40:223-228.
206. Krzeczowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of free amino acids in the blood of patients with myocardial infarction using a new method of photometry of the negative printed chromatograms. Pol Arch Med Wewn 1968;41:361-368.
207. Krzeczowska, I., Czerniak, Z., Burzynski, S. Quantitative determinations of carbohydrates and their statistical analysis, II. Analysis of variance for four-crossed classification and Tukey confidence intervals. Chem Anal 1968;13:1229-1238.
208. Burzynski, S. Investigations on amino acids and peptides in blood serum of healthy people and patients with chronic renal insufficiency. 1968; Lublin, Poland: 274 pp (doctoral dissertation).
209. Krzeczowska, I., Burzynski, S., Czerniak Z. Quantitative determination of amino acids using photometry of negative printed chromatograms. Ann Univ MC Sklodowska 1966;21:125-134.
210. Krzeczowska, I., Czerniak, Z., Burzynski, S. The application of the negative printed chromatograms for quantitative determination of free amino acids in the blood of healthy people. Ann Univ MC Sklodowska 1966;21:313-322.
211. Krzeczowska, I., Burzynski, S., Czerniak, Z. Investigations on the possibility of the determination of mushroom species on the basis of the composition of their amino acids. Ann Univ MC Sklodowska 1965;20:221-229.
212. Krzeczowska, I., Czerniak, Z., Burzynski, S. Free and bound amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1965;20:303-312.
213. Krzeczowska, I., Czerniak, Z., Burzynski, S. Bound amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1964;19:329-336.
214. Krzeczowska, I., Burzynski, S., Czerniak, Z. Free amino acids of some edible mushrooms. Ann Univ MC Sklodowska 1964;19:321-328.

SELECTED ABSTRACTS OF PRESENTATIONS BY S.R. BURZYNSKI AND ASSOCIATES

1. Burzynski, S.R. Current innovations in cancer treatment. War on cancer, Texas chapter. Presented at The Truth About Cancer LIVE; October 5, 2017 – October 7, 2017; Orlando, FL.
2. Burzynski, S.R. Precision therapy of glioblastoma. Presented at BIT's 8th Annual World Congress of NeuroTalk-2017; May 22, 2017 – May 24, 2017; Barcelona, Spain.
3. Burzynski, S.R., Janicki, T., Burzynski, G. Treatment of children with primary CNS tumors and

leptomeningeal, disseminated and/or multicentric disease in phase II studies with antineoplastons A10

**Burzynski** 3rd International Symposium on Pediatric Neuro-Oncology (ISPNO); June
HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC ▾ SERVICES ▾

4 Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and
CLINICAL TRIALS ▾ INFO ▾ CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)
AS2-1 in children with recurrent, refractory or progressive primary brain tumors based on protocol

(<https://www.burzynskiclinic.com>)
BT-02. Presented at the 3rd International Symposium on Pediatric Neuro-Oncology (ISPNO);
June 28, 2014 – July 2, 2014; Singapore.

5. Burzynski, G., Janicki, T., Burzynski, S.R., Marszalek, A. Long-term survival (over 20 years) and
pathologically confirmed complete response in pediatric anaplastic astrocytoma: a case report.
HG-017. Presented at the 16th International Symposium on Pediatric Neuro-Oncology (ISPNO); June
28, 2014 – July 2, 2014; Singapore.

6. Janicki, T., Burzynski, S.R., Burzynski, G., Marszalek, A. Long-term survival (over 20 years), complete
response and normal childhood development in medulloblastoma (PNET) without recurrence: a case
report. MB-039-020. Presented at the 16th International Symposium on Pediatric Neuro-Oncology
(ISPNO); June 28, 2014 – July 2, 2014; Singapore.

7. Burzynski, G., Burzynski, S.R., Janicki, T., Marszalek, A. A phase II study of antineoplastons A10 and
AS2-1 in adult patients with recurrent glioblastoma multiforme based on protocol BT-21. Presented at
the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology in conjunction with the 18th
Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology; November 21-24,
2013; San Francisco, California, USA.

8. Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1
in pediatric recurrent diffuse intrinsic pontine glioma. Presented at the 4th Quadrennial Meeting of the
World Federation of Neuro-Oncology in conjunction with the 18th Annual Scientific Meeting and
Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California,
USA.

9. Janicki, T., Burzynski, S., Burzynski, G., Marszalek, A. A phase II study of antineoplastons A10 and AS2-1
(ANP) in children with high-grade glioma (Protocol BT-06). Presented at the 4th Quadrennial Meeting of
the World Federation of Neuro-Oncology in conjunction with the 18th Annual Scientific Meeting and
Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California,
USA.

10. Burzynski, S., Janicki, T., Burzynski, G., Marszalek, A. Long-term survival (over 13 years) in a child with
recurrent diffuse pontine gliosarcoma: A case report. Presented at the 4th Quadrennial Meeting of the
World Federation of Neuro-Oncology in conjunction with the 18th Annual Scientific Meeting and
Education Day of the Society for Neuro-Oncology; November 21-24, 2013; San Francisco, California,
USA.

11. Burzynski, S.R. Molecular profiling in oncology practice: The results of treatment in a group of 1,633
patients.” Presented at BIT’s 4th Annual World Cancer Congress – 2011; May 22-25, 2011; Dalian,
China.

12. Burzynski, S.R, Weaver, R.A., Janicki, T.J., Burzynski, G.S., Szymkowski, B., Acelar, S.S. OT-15. Preliminary
results of a phase II study of antineoplastons A10 and AS2-1 (ANP) in adult patients with recurrent
mixed gliomas. Presented at the 15th Annual Scientific Meeting of the Society for Neuro-Oncology;
November 16-22, 2010; Montreal, Quebec, Canada.

13. Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. CB-15. Targeting microRNAs in glioma cells with the 15th Annual Scientific Meeting of the Society for Neuro-Oncology; the 15th Annual Scientific Meeting of the Society for Neuro-Oncology; Quebec, Canada.

14. Burzynski, S.R., Weaver, R.A., Janicki, T., E. Szymkowski, B., Acelar, S.S., Burzynski, G.S. A phase II study of antineoplaston A10 and AS2-1 injections in children with low-grade astrocytomas. Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO), June 20-23, 2010; Vienna, Austria.

15. Patil, S., Burzynski, S.R, Mrowczynski, E., Grela, K. Antineoplastons initiate caspase induced apoptosis by suppressing survivin expression in U87 glioblastoma cells. Presented at the 14th International Symposium on Pediatric Neuro-Oncology (ISPNO); June 20-23, 2010; Vienna, Austria.

16. Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B., Burzynski, G.S. Phase II study of antineoplastons A10 and AS2-1 in patients with brainstem glioma. Protocol BC-BT-11. Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

17. Weaver, R.A., Szymkowski, B., Burzynski, S.R. Over a 10-year survival and complete response of a patient with diffuse intrinsic brainstem glioma (DBSG) treated with antineoplastons (ANP). Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

18. Patil, S., Burzynski, S.R., Chittur, S., Mrowczynski, E., Grela, K. Antineoplastons inhibit MCM complex in glioblastoma cells. Presented at the 3rd Quadrennial Meeting of the World Federation of Neuro-Oncology jointly with the 6th Meeting of the Asian Society for Neuro-Oncology; May 11-14, 2009; Yokohama, Japan.

19. Burzynski, S.R. New research on molecular mechanisms and prevention of Alzheimer's disease. Presented at the 17th Annual world Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies, Spring 2009 Session; April 21-April 25, 2009; Orlando, Florida.

20. Burzynski, S. Life extension through application of chromatin remodeling agents. Presented at the 7th Anti-Aging Medicine World Congress & Medispa; March 19-March 21, 2009; Monte-Carlo, Monaco.

21. Marquis, A., Kubove, E., Walczak, M., Burzynski, S. Hepatocellular carcinoma, recurrent after standard therapy, successfully treated with a combination of targeted therapies. Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.

22. Weaver, R., De Leon, L., Burzynski, S. A complete response in a patient with inoperable adenocarcinoma of the head of the pancreas treated with a combination of gene-targeted therapies. Presented at the 20th International Congress on Anti-Cancer Treatment; February 3-February 6, 2009; Paris, France.

23. Burzynski, S.R. The Coming Pandemic of Liver Cancer. In Search of Genomic Solutions. Presented at the 16th Annual World Congress of A4M, Winter 2008 Session; December 12-December 15, 2008; Las Vegas, Nevada.

24. Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Samuel, S., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 (ANP) in patients with newly diagnosed anaplastic astrocytoma: A preliminary report. Presented at the 13th Annual Scientific Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.

25. Burzynski, S.R., Patil, S., Chittur, S., Mrowczynski, E., Grela, K. Antineoplaston AS2-1 affects cell cycle checkpoints leading to apoptosis in human glioblastoma cells. Presented at the 13th Annual Scientific

Meeting of the Society for Neuro-Oncology; November 20-November 23, 2008; Las Vegas, Nevada.

26. Burzynski, S.R., Ka-Musial, E., Chittur, S., Gupta, V., Sarangi, R. Pathway analysis of the Hsp90 signaling pathway in the brains of amyloid. Presented at the 15th Annual World Congress on Anti-Aging and Aesthetic Medicine (DCAAAM); November 7-November 9, 2008; Dubai.
27. Burzynski, S.R. Practical Application of Gene Silencing Theory of Aging. Life Extension in Animals and Human Clinical Trials. Presented at the Dubai Congress on Anti-Aging and Aesthetic Medicine (DCAAAM); November 7-November 9, 2008; Dubai.
28. Burzynski, S.R. Antineoplastons and Targeted Gene Therapy. Presented at ACAM Scientific Conference; October 15-October 19, 2008; Las Vegas, Nevada.
29. Burzynski, S.R., Weaver, R., Janicki, T., Szymkowski, B., Walczak, M., Burzynski, G. Phase II study of antineoplastons A10 and AS2-1 infusions (ANP) in patients with recurrent anaplastic astrocytoma. Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.
30. Patil, S., Burzynski, S.R., Chittur, E., Mrowczynski, K.G. The ingredients of antineoplaston AS2-1 down-regulate glycolysis pathways in glioblastoma cells. Presented at the European Association for NeuroOncology (EANO); September 12-September 14, 2008; Barcelona, Spain.
31. Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animal testing and human clinical trials. Presented at the European Congress on Anti-Aging & Aesthetic Medicine (ECAAAM); September 11-September 14, 2008; Düsseldorf, Germany.
32. Burzynski, S.R., Weaver, R., Janicki, T., Walczak, M., Szymkowski, B., Samuel, S. Phase II study of antineoplastons A10 and AS2-1 (ANP) in children with optic pathway glioma: A preliminary report. Presented at the 13th International Symposium on Pediatric Neuro-Oncology; June 29-July 2, 2008; Chicago, Illinois.
33. Burzynski, S.R. Genome, Epigenome and Aging. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.
34. Burzynski, S.R. Personalized Cancer Treatment in Genomics Era. Presented at the First Annual Iberian Congress on Anti-Aging Medicine and Biomedical Technologies; May 29-31, 2008; Estoril, Portugal.
35. Burzynski, S.R. Practical application of gene silencing theory of aging. Life extension in animals and human clinical trials. Presented at the 16th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; April 25-27, 2008; Orlando, Florida.
36. Burzynski, S.R. Antineoplaston peptides in treating cancer. Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008; San Francisco, California.
37. Burzynski, S.R. Anti-Aging peptides—a new frontier in healing. Presented at the 2008 Orthomolecular Health-Medicine conference; February 29-March 2, 2008; San Francisco, California.
38. Burzynski, S.R. Genomic approach to cancer treatment. Presented at the 15th Annual World Congress on Anti-Aging Medicine and Regenerative Biomedical Technologies; December 12-15, 2007; Las Vegas, Nevada.
39. Burzynski, S.R. Genomics in Cancer Treatment. Presented at the 1st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.
40. Burzynski, S.R. Epigenomic Approach to Anti-Aging. Presented at the 1st Annual India Conference on Anti-Aging and Regenerative Medicine; November 16-18, 2007; Mumbai, India.
41. Burzynski, S.R., Weaver, R.A., Szymkowski, B. A case report of a complete response and 20-year survival

of a patient with a recurrent, diffuse, intrinsic brainstem anaplastic astrocytoma. Presented at the 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas.

42. Burzynski, S.R., Tempczyk-Russell, A., Ilkowska-Musial, E., Opela, K. Phenylacetate, glutamine (P) and phenylacetate (PN) integratively to produce detachment-induced apoptosis/anoikis in glioblastoma cells. Presented at the Society for Neuro-Oncology 12th Annual Scientific Meeting; November 15-18, 2007; Dallas, Texas. (<https://www.burzynskiclinic.com>)

43. Burzynski, S.R., Tempczyk-Russell, A., Ilkowska-Musial, E. Amyloid precursor protein (APP) and related protein fragmentation in consolidation of memory. Presented at Neuroscience 2007, the Society's Annual Meeting; November 3-7, 2007; Sand Diego, California.

44. Burzynski, S.R. Epigenomic approach to anti-aging. Presented at: 4th Congresso Internacional de Antienvhecimento; October 26-27, 2007; Sao Paulo, Brazil.

45. Burzynski, S.R. Nutrition and ageing : Gene silencing or gene activation. Presented at: 10th European Nutrition Conference; July 10-13, 2007; Paris, France.

46. Burzynski, S.R. La solution génétique contre le vieillissement. Presented at: Anti-Aging Medicine World Congress; March 22-24, 2007; Monte Carlo.

47. Burzynski, S.R. Genetics of Brain Aging (II). Genetic Mechanisms in Encoding and Consolidation of Memory. Presented at: 14th Annual International Congress on Anti-Aging Medicine; December 7-10, 2006; Las Vegas, Nevada.

48. Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.J., Khan, M.I., Dolgopopov, V. Treatment of multicentric brainstem gliomas with Antineoplastons (ANP) A10 and AS2-1. Presented at the Society for Neuro-Oncology's 11th Annual Meeting; November 16-19, 2006; Orlando, Florida.

49. Burzynski, S.R., Christensen, R., Ilkowska-Musial, E. Memory processing proteins have common amino acid sequences with Scotophobin. Presented at: Neuroscience 2006, the Society's 36th annual meeting; October 14-18, 2006; Atlanta, Georgia.

50. Burzynski, S.R., Weaver, R.A., Janicki, T.J., Szymkowski, B., Jurida, G.F. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in adult patients with diffuse intrinsic brainstem gliomas. Presented at: The European Association for Neuro Oncology: 7th Congress Vienna Hofburg Congress Center; September 14-17, 2006; Vienna, Austria.

51. Burzynski, S.R. Genetics of Brain Aging (I). Gene Silencing in Neurons. Presented at: 14th Annual International Congress on Anti-Aging Medicine; July 14-16, 2006; Chicago, Illinois.

52. Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

53. Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (III) Aminocare Products and Aging of the Brain. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

54. Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (II) Aminocare Products and Skin Aging. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

55. Burzynski, S.R. The Genetic Solution for Anti-Aging. Workshop (I) Theory and Age-Management with Aminocare Products. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan

56. Burzynski, S.R. Gene Silencing Theory of Aging. Presented at: 1st Anti-Aging International Symposium and Exposition; June 16-18, 2006; Tokyo, Japan.

57. Burzynski, S.R., Weaver, R.A., Janicki, T.J., Jurida, G.F., Szymkowski, B.G., Kubove, E. Phase II studies of Antineoplaston A10 (ANP) in children with newly diagnosed diffuse, intrinsic brainstem gliomas. Presented at: National Symposium on Pediatric Neuro-Oncology; June 6-9, 2006; Nashville, Tennessee.
58. Burzynski, S.R. Chronobiology of Aging. Presented at: International Danube Symposium for Neurological Sciences and Geriatric Education, May 10-13, 2006, Kufing-Dolny, Poland.
59. Burzynski, S.R. The Genetic Solution for Anti-Aging. Presented at: 14th International Congress on Anti-Aging Medicine; April 7-9, 2006; Orlando, Florida.
60. Burzynski, S.R., Janicki, T.J., Weaver, R.A., Szymkowski, B.G., Jurida, G.F. Burzynski, B. Phase II studies of antineoplastons A10 and AS2-1 (ANP) in patients with recurrent, diffuse intrinsic brain stem gliomas. Presented at the 17th International Congress on Anti-Cancer Treatment; January 30-February 2, 2006; Paris, France.
61. Burzynski, S.R. Master Clock of Life (II). How to Turn the Clock Back. Presented at: XIII International Congress on Anti-Aging Medicine; December 8-12, 2005; Las Vegas, Nevada.
62. Burzynski, S.R. Master Clock of Life (I) "Junk DNA" and Promotors Region as Major Components of the Clock. Presented at: XIII International Congress of Anti-Aging Medicine; August 19-21, 2005; Chicago, Illinois.
63. Burzynski, S.R., Weaver, R.A., Janicki, T.J., Burzynski, B., Jurida, G. Targeted therapy with ANP in children less than 4 years old with inoperable brain stem gliomas. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.
64. Weaver, R.A., Burzynski, S.R., Janicki, T.J., Burzynski, B., Jurida, G., Szymkowski, B. Long-term survival in patients with glioblastoma multiforme treated in phase II studies with ANP. Presented at: 2nd Quadrennial meeting of the World Federation of Neuro-Oncology/ 6th meeting of the European Association of NeuroOncology; May 5-8, 2005; Edinburgh, Scotland, UK.
65. Burzynski, S.R., Janicki, T.J., Weaver, R.A., Burzynski, B. Targeted therapy with Antineoplastons A10 and AS2-1 (ANP) of high grade, recurrent and progressive brain stem glioma. Presented at the 16th International Congress on Anti-Cancer Treatment; February 1-4, 2005; Paris, France.
66. Burzynski, S.R. Presented at: The Cleveland Clinic Neuro-Oncology 2005: Current Concepts; January 29-31, 2005; Lake Buena Vista, FL, USA.
67. Burzynski, S.R., Jacquet, A., Moore, N., Musial, L. Gene silencing theory of aging: the clinical trial supporting the theory. Presented at: American Academy of Anti-Aging Medicine (A4M) Conference on Anti-Aging Medicine, December 2-5, 2004; Las Vegas, USA.
68. Burzynski, S.R., Weaver, R. Bestak, M., Lewy, R.I., Janicki, T., Jurida, G., Szymkowski, B., Khan, M., Dolgoplov, V. Long-term survivals in phase II studies of Antineoplastons A10 and AS2-1 (ANP) in patients with diffuse intrinsic brain stem glioma. Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.
69. Weaver, R.A., Burzynski, S.R., Bestak, M., Lewy, R.I., Janicki, T.J., Szymkowski, B., Jurida, G., Khan, M.I., Dolgoplov, V. Phase II study of Antineoplastons A10 and AS2-1 (ANP) in recurrent glioblastoma multiforme. Presented at: 9th Annual Meeting Society for Neuro-Oncology, November 18-21, 2004; Toronto, Canada.
70. Burzynski, S.R., Janicki, T., Weaver, R., Jurida, G., Szymkowski, B., Khan, M., Dolgoplov, V. Clinical

application of body epigenetic system. Multi-targeted therapy for primary brain tumors.

 **Burzynski** Clinic on Magic Bullets Celebrating Paul Ehrlich's 150th Birthday; September, 2003
HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/)) **OUR CLINIC** ▼ **SERVICES** ▼

CLINICAL TRIALS ▼ **INFO** ▼ **CONTACT** ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))
71. Burzynski, S.R. The new generation of food supplements effecting gene expression. Presented at 2nd Congress Food, Nutrition and Health in Poland Integrated with European Union; June 23-26, 2004; Warsaw, Poland.

(<https://www.burzynskiclinic.com>)

72. Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J., Szymkowski, B., Jurida G., Khan, M., Dolgoplov, V. Treatment of Primitive Neuroectodermal Tumors (PNET) with Antineoplastons A10 and AS2-1 (ANP). Preliminary Results of Phase II Studies. Presented at 11th International Symposium on Pediatric Neuro-Oncology; June 13-16, 2004; Boston, MA.
73. Burzynski, S.R., Weaver, R.A., Bestak, M., Janicki, T.J., Jurida G., Szymkowski, B., Khan, M., Dolgoplov, V. Phase II Studies of Antineoplastons A10 and AS2-1 (ANP) in Children with Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System. A Preliminary Report. Presented at 11th International Symposium on Pediatric Neuro-Oncology; June 13-16, 2004; Boston, MA.
74. Burzynski, S.R., Lewy, R.I., Axler, M., Janicki, T.J. Treatment of Malignant Mesothelioma (MM) with Sodium Phenylbutyrate. Presented at the 15th International Congress on Anti-Cancer Treatment; February 9-12, 2004, Paris, France.
75. Waldbillig, R.J., Mrowczynski, E., Burzynski, S.R. Phenylacetic acid (PN) and Phenylacetylglutamine (PG): Mechanism of Uptake and changes in Epigenetic-Mechanisms Regulating Gene Expression. Presented at the 2nd Annual American Association for Cancer Research (AACR) International Conference; October 26-30, 2003, Phoenix, AZ.
76. Burzynski, S.R. Interaction of antineoplastons with genome in cancer and aging. Presented at: Annual Meeting of International Academy of Oral Medicine and Toxicology; September 12-13, 2003, New Orleans, Louisiana.
77. Burzynski, S.R. Antineoplastons in: Cancer Treatment and Age Management Therapy. Presented at American Collage for Advancement in Medicine (ACAM); May 16, 2003, Washington, DC.
78. Burzynski, S.R. The State of Antineoplaston Research – Spring of 2003. Presented at the 5th Annual Comprehensive Cancer Care Conference; April 11, 2003, Washington, DC.
79. Waldbillig, R.J., Burzynski, S.R. The application of chromatography to the pharmacokinetic study of Antineoplastons A10 and AS2-1. Presented at the 3rd International Symposium of Chromatography and Natural Products; June 12-15, 2002, Lublin, Poland.
80. Burzynski, S.R. Presented at 'Health-Trends 2000', The 2nd International Conference; August 27-29, 1999, Copenhagen, Denmark.
81. Burzynski, S.R. Phase II Trial of Antineoplaston A10 and AS2-1 in Brain Stem Glioma. Presented at International Conference on Integrative Medicine; May 1, 1999, Seattle, Washington, USA.
82. Czerwinski, A., Klimczak, M.W., Burzynski, S.R. Enancjoselektywna analiza skladnikow Antyneoplastonu A10 metoda HPLC. Presented at the XVII Naukowy Zjazd Polskiego Towarzystwa Farmaceutycznego, September 1998, Krakow, Poland.
83. Burzynski, S.R. Gene Therapy with Antineoplastons. Presented at Comprehensive Cancer Care; June, 1998, Washington, D.C., USA.
84. Burzynski, S.R. Antineoplastons in the Treatment of Malignant Brain Tumors. Presented at 5th International Conference of Anti-Aging Medicine and Biomedical Technology; December, 1997, Las

Vegas, Nevada, USA.

- 
85. Burzynski, S.R. Innovative Cancer Therapies. Presented at 4th Annual Conference on Home (HTTPS://WWW.BURZYNSKICLINIC.COM) Biotechnology; Dec., 1994; Las Vegas, Nevada, USA.
86. Burzynski, S.R. Antineoplastons Today. Presented at the First International Congress On Alternative & Complementary Medicine; May, 1995; Washington, DC USA.
87. Sobysak, Pawluczak, R., Burzynski, S.R. Jutland Characterization of Antineoplaston AS2-1 by Human Hepatoma Cells. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
88. Lee, S.S., Burzynski, S.R. Synergistic Inhibitory Effect of Antineoplaston A5 and Thymidine on the Growth of Human Cancer Cell Lines. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
89. Liao, M.C., Liao, C.P., Burzynski, S.R. Helper Inducers of Terminal Differentiation. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
90. Burzynski, S.R., Szymkowski, B., Kubove, E. Phase II Clinical Trials of Antineoplaston AS2-1 in Asymptomatic HIV Infection. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
91. Burzynski, S.R., Kubove, E., Szymkowski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in High Grade Glioma. Presented at the 18th International Congress of Chemotherapy; June, 1993; Stockholm, Sweden.
92. Kleinrok, Z., Burzynski, S.R., Juskiewicz, M., Chodkowska, A., Feldo, M. The Influence of Antineoplaston A5 on the Central Dopaminergic Structures. Presented at: 11th Congress of the Polish Pharmacological Society; September, 1992; Gdansk, Poland.
93. Burzynski, S.R., Kubove, E., Szymkowski, B., Burzynski, B. Phase II Clinical Trials of Novel Differentiation Inducer – Antineoplaston AS2-1 in AIDS and Asymptomatic HIV Infection. VIII International Conference on AIDS/III STD World Congress; July, 1992; Amsterdam, The Netherlands.
94. Burzynski, S.R. Differentiation Inducers-Possible Agents for Cancer Therapy in Pregnancy. Presented at the World Congress of Prenatal and Perinatal Psychology and Medicine; May, 1992; Krakow, Poland.
95. Burzynski, S.R., Kubove, E., Burzynski, B. Phase II Clinical Trials of Antineoplaston A10 and AS2-1 Infusions in Astrocytoma. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.
96. Liao, M.C., Luong, Y., Liao, C.P., Burzynski, S.R. Prevention of Drug-Induced DNA Hypermethylation by Antineoplastons. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.
97. Lee, S.S., Burzynski, S.R. Synergistic Effect of Antineoplaston A5 and Retinoic Acid on the Induction of Human Promyelocytic Leukemia line HL-60. Presented at the 17th International Congress of Chemotherapy; June, 1991; Berlin, Germany.
98. Liao, M.C., Lee, S.S., Liao, C.P., Burzynski, S.R. Efficient Methylation when Locked in Place Becomes a Major Problem of Cancer. Presented at the 82nd Annual Meeting of the American Association for Cancer Research, May, 1991, Houston, Texas, USA.
99. Burzynski, S.R. Presented at: The World Research Foundation Congress, October 7, 1990, Los Angeles, CA, USA.
100. Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Study of Radioactive Antineoplaston

AS2-1 Following Oral Administration in Rats. Presented at the 9th International Symposium on Future Trends in Chemotherapy; March, 1990, Geneva, Switzerland.

102. Liao, M.C., Lee, S.S., Burzynski, S.R. Treatment of Hormonally Refractory Cancer of the Prostate with Antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy; March, 1990, Geneva, Switzerland.

103. Liao, M.C., Lee, S.S., Burzynski, S.R. Antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy; March, 1990, Geneva, Switzerland.

104. Liao, M.C., Lee, S.S., Burzynski, S.R. Antineoplaston AS2-1. Presented at the 9th International Symposium on Future Trends in Chemotherapy; March, 1990, Geneva, Switzerland.

105. Liao, M.C., Lee, S.S., Burzynski, S.R. Hypomethylation of Nucleic Acids: A Key to the Induction of Terminal Differentiation. Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.

106. Burzynski, S.R. Antineoplastons – New Way for Cancer Chemotherapy. Presented at the 10th Congress of the Polish Pharmacological Society, September, 1989, Bialystok, Poland.

107. Liao, M.C., Lee, S.S., Burzynski, S.R. Role of Methylation Enzymes in Directing Phenotypic Changes. Presented at the 41st Annual Symposium on Fundamental Cancer Research. D. Anderson Hospital and Tumor Institute; October, 1988; Houston, Texas, USA.

108. Liao, M.C., Khalid, M., Burzynski, S.R. Differentiation Inducing Factors of Antineoplaston A5. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

109. Khalid, M., Burzynski, S.R. Phenylacetylglutamine Derivatives as Novel Chemotherapeutic Agents. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

110. Lee, S. S., Burzynski, S.R. Terminal Differentiation of HL-60 Human Promyelocytic Leukemia Cells Induced by Antineoplaston A2. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

111. Ashraf, A.Q., Kampalath, B.N., Burzynski, S.R. Pharmacokinetic Analysis of Antineoplaston A10 Injections Following Intravenous Administration in Rats. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

112. Burzynski, S.R. Treatment of Malignant Brain Tumors with Antineoplastons. Presented at the 8th International Symposium on Future Trends in Chemotherapy; March, 1988; Pisa, Italy.

113. Liao, M.C., Lee, S.S., Burzynski, S.R. Modulation of Tumor Methylation Complex Isozymes as a Decisive Factor in the Induction of Differentiation by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

114. Lee, S.S., Burzynski, S.R. Induction of Differentiation of HL-60 Human Promyelocytic Leukemic Cells by Antineoplaston A5. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

115. Kampalath, B.N., Liao, M.C., Burzynski, B., Burzynski, S.R. Protective Effect of Antineoplaston A10 in Hepatocarcinogenesis Induced by Aflatoxin B 1. Presented at the 4th European Conference on Clinical Oncology and Cancer Nursing; November, 1987; Madrid, Spain.

116. Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston A3. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

117. Liao, M.C., Ashraf, A.Q., Burzynski, S.R. Active Anticancer Components of Antineoplaston Formulations. Presented at the 10th International Congress of Pharmacology, August, 1987, Sydney, Australia.

116. Ashraf, A.Q., Burzynski, S.R. Comparative Study of Antineoplaston A10 Levels in Plasma of Healthy
presented at the 15th International Congress of Chemotherapy; July,
1987; Istanbul, Turkey. [HOME \(HTTPS://WWW.BURZYNSKICLINIC.COM/\)](https://www.burzynskiclinic.com/) [OUR CLINIC](#) ▼ [SERVICES](#) ▼
117. Burzynski, S.R. Treatment of Bladder Cancer with Antineoplaston Formulations. Presented at the 15th
International Congress of Chemotherapy; July, 1987; Istanbul, Turkey. [CONTACT \(HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/\)](https://www.burzynskiclinic.com/)
118. Burzynski, S.R. Antineoplaston B. Basic Research and Clinical Applications. Presented at the 15th
International Congress of Chemotherapy; July, 1987; Istanbul, Turkey. [\(https://www.burzynskiclinic.com\)](https://www.burzynskiclinic.com/)
119. Burzynski, S.R. Modeling Studies Suggest the Modified Dipeptide Analog Phenylacetyl-amino-2,
6-piperidinedione May Interact with DNA. Presented at the 15th International Congress of
Chemotherapy; July, 1987; Istanbul, Turkey.
120. Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Oral Formulation of Antineoplaston
AS2-1. Presented at the 15th International Congress of Chemotherapy; July, 1987; Istanbul, Turkey.
121. Lee, S.S., Burzynski, S.R. A Unique Pattern of Growth Inhibition by Antineoplaston A5 on a T-Leukemia
Cell Line. Presented at the 14th Annual meeting of the International Society of Oncodevelopmental
Biology and Medicine; August, 1986; Helsinki, Finland.
122. Liao, M.C., Kampalath, B.N., Szopa, M., Burzynski, B., Burzynski, S.R. Chemo-surveillance: A Novel
Concept on the Natural Defense Mechanism Against Cancer. Presented at the 14th Annual meeting of
the International Society of Oncodevelopmental Biology and Medicine; August, 1986; Helsinki, Finland.
123. Kampalath, B.N., Liao, M.C., Burzynski, B., Burzynski, S.R. Chemoprevention by Antineoplaston A10 on
Benzo (1) pyrene Induced Pulmonary Neoplasia. Presented at the 5th Mediterranean Congress of
Chemotherapy; October, 1986; Cairo, Egypt.
124. Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A2 Injections. Presented at the
14th International Cancer Congress; August, 1986; Budapest, Hungary.
125. Hendry, L.B., Lehner, A.F., Muldoon, T.G., Copland, J.A., Mahesh, V.B., Mills, T.M., Burzynski, S.R.
Investigations of the Mode of Action of Antineoplaston A10: Evidence for Binding to DNA. Presented at
the 14th International Cancer Congress; August, 1986; Budapest, Hungary.
126. Burzynski, S.R., Kubove, E., Burzynski, B. Phase I Clinical Studies of Antineoplaston A5 Injections.
Presented at the III World Conference on Clinical Pharmacology and Therapeutics; July, 1986;
Stockholm, Sweden.
127. Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A3 Injections. Presented at the 7th
International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
128. Khalid, M., Burzynski, S.R. N,N'-disubstituted L-isoglutamines as Novel Cancer Chemotherapeutic
Agents. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986;
Pisa, Italy.
129. Lee, S.S., Mohabbat, M.O., Burzynski, S.R. In Vitro Cancer Growth Inhibition and Acute Animal Toxicity
Studies of Antineoplaston A3. Presented at the 7th International Symposium on Future Trends in
Chemotherapy; May, 1986; Pisa, Italy.
130. Lehner, A.F., Copland, J.A., Muldoon, T.G., Burzynski, S.R., Hendry, L.B. In Vitro Studies of the
Stereospecificity of Antineoplaston A10 Interaction with Double-stranded DNA. Presented at the 7th
International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
131. Ashraf, A.Q., Kampalath, B.N., Liao, M.C., Burzynski, S.R. Pharmacokinetic Study of Radioactive
Antineoplaston A10 Following Oral Administration in Rats. Presented at the 7th International

Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.

132. Burzynski, S.R., Copland, J.A., Lehner, A.F. Stereochemical Modeling Studies with Antineoplaston A10 with DNA. Presented at the 7th International Symposium on Future Trends in Chemotherapy; May, 1986; Pisa, Italy.
133. Burzynski, S.R., Kubove, E. Phase I Clinical Studies of Antineoplaston A10 Injections. Presented at the 2nd Annual Conference of Indian Society of Oncology; February, 1986; Bombay, India.
134. Burzynski, S.R., Lehner, A.F., Hendry, L.B. Putative Mechanism of Action of a Novel Peptide Analog with Apparent Antineoplastic Activity: Stereospecific interaction with DNA. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.
135. Liao, M.C., Szopa, M., Burzynski, B., Burzynski, S.R. Quantitative Assay of Plasma and Urinary Peptides as Aid for Evaluation of Cancer Patients Undergoing Antineoplaston Therapy. Presented at the 13th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine; September, 1985; Paris, France.
136. Hendry, L.B. Lehner, A.F., Burzynski, S.R. A Novel Naturally-occurring Peptide Analog with Apparent Antineoplastic Activity May Interact with DNA. Presented at the International Symposium, Cancer: Perspective for Control; August, 1985; Beijing, China.
137. Hendry, L.B., Lehner, A.F., Burzynski, S.R. Spectroscopic Studies of the Interaction of Antineoplaston A10 with DNA. Presented at the 12th Symposium of the International Association for Comparative Research on Leukemia and Related Disease; July, 1985; Hamburg, Germany.
138. Burzynski, S.R. Phase I Clinical Studies of Antineoplaston AS2-5 Injections. Presented at the 14th International Congress of Chemotherapy; June, 1985; Kyoto, Japan.
139. Burzynski, S.R., Burzynski, B., Mohabbat, M.O. Phase I Clinical Studies of Antineoplaston AS2-1 Injection. Presented at the 3rd European Conference on Clinical Oncology and Cancer Nursing; June, 1985; Stockholm, Sweden.
140. Liao, M.C., Burzynski, S.R. Alteration of Methylation Complex of Isoenzymes Critical to Malignant Evolution. Presented at the 12th Annual Meeting of the International Society for Oncodevelopmental Biology and Medicine, October, 1984; Houston, USA.
141. Burzynski, S.R., Mohabbat, M.O., Burzynski, B. Toxicology Studies of Oral Formulation of Antineoplaston A10 in Cancer Patients. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.
142. Lee, S. S., Mohabbat, M.O., Burzynski, S.R. Tissue Culture and Animal Toxicity Studies of Antineoplaston A2. Presented at the 6th International Symposium on Future Trends in Chemotherapy; May, 1984; Pisa, Italy.
143. Burzynski, S.R., Hendry, L.B., Mohabbat, M.O., Liao, M.C., Khalid, M., Burzynski, B. Purification, Structure Determination, Synthesis and Animal Toxicity Studies of Antineoplaston A10; PS 12.4.11-4. Presented at the 13th International Congress on Chemotherapy, TOM 17; August, 1983; Vienna, Austria.
144. Burzynski, S.R. Recent Advances in Ultramicroanalysis of Biologically Active Peptides. Presented at the 30th Southwest Regional American Chemical Society meeting, 1974; Houston, Texas.
145. Ungar, G., Burzynski, S.R. Detection of a Behavior-inducing Peptide (Scotophobin) in Brain by Ultramicroanalytical Method. Fed Proc., 1972; 31: 398.
146. Burzynski, S.R., Czerniak, Z. The Photometry of Negative Printed Chromatograms and its Application

for Amino Acid Analysis in Human Blood. Biuletyn VII Ogólnopolskiej Konferencji Studenckich Kol

1966; Poznań, Poland.



HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/))

BURZYNSKI CLINIC ▼

SERVICES ▼

PATENTS



CLINICAL TRIALS ▼ *First, Do No Harm!*

INFO ▼

CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))

(<https://www.burzynskiclinic.com>)
AIDS

Patent No.	National Patent No.	Country	Title
638869		Australia	Pharmaceutical compositions for use in treating AIDS.
500905	ATE135,217	Austria	Pharmaceutical compositions for use in treating AIDS.
500905		Belgium	Pharmaceutical compositions for use in treating AIDS.
500905		Denmark	Pharmaceutical compositions for use in treating AIDS.
500905		Europe	Pharmaceutical compositions for use in treating AIDS.
500905		France	Pharmaceutical compositions for use in treating AIDS.
500905	69117923	Germany	Pharmaceutical compositions for use in treating AIDS.
500905	3019970	Greece	Pharmaceutical compositions for use in treating AIDS.
500905		Italy	Pharmaceutical compositions for use in treating AIDS.
500905		Luxembourg	Pharmaceutical compositions for use in treating AIDS.

28633	Philippines	Methods for treating AIDS.
81889	Singapore	Pharmaceutical compositions for use in treating AIDS.
91/6977	South Africa	Pharmaceutical compositions for use in treating AIDS.
500905	Spain	Pharmaceutical compositions for use in treating AIDS.
500905	Sweden	Pharmaceutical compositions for use in treating AIDS.
500905	Switzerland	Pharmaceutical compositions for use in treating AIDS.
500905	United Kingdom	Pharmaceutical compositions for use in treating AIDS.
5089508	USA	Methods for treating AIDS.
5254587	USA	Methods for treating AIDS.

AMINOCARE

Patent No.	National Patent No.	Country	Title
Pending	181/2004	Arab Emirates	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

(<https://www.burzynskiclinic.com>)

Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

Pending	PI0214430-1	Brazil	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
2468133		Canada	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
ZL02823606.8		China	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
009516		Eurasia	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy. The Eurasian patent has been validated in the following contracting countries: Azerbaijan (AZ), Kazakhstan (KZ), and Russia (RU).
1450781		Europe	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
1450781		France	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
1450781	DE60212393T2	Germany	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
Pending	P04-02240	Hungary	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

(https://www.burzynskiclinic.com)

	Country	Title
ID0018257	Indonesia	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
1450781	Ireland	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
162141	Israel	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
4614660	Japan	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
247856	Mexico	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
532833	New Zealand	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
332858	Norway	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
1-2004-500758	Philippines	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
953483	Republic of Korea	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

Patent No.	National Patent No.	Country	Title
104603		Singapore	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
21542		Slovenia	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
2004/4115		South Africa	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
78977		Ukraine	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.
7427619132		USA	Formulation of amino acids and riboflavin useful to reduce toxic effects of cytotoxic chemotherapy.

ATHEROSCLEROSIS AND RESTENOSIS

Patent No.	National Patent No.	Country	Title
757114		Australia	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
1171110		Austria	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

(https://www.burzynskiclinic.com)

Study ID	Country	Title	
2345409	Canada	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	
1171110	Europe	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	
69916330T2	France	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	
1117110	69916330T2	Germany	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
1045253	Hong Kong	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	
1171110	Ireland	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	
1171110	Italy	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	
4536258	Japan	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	
1171110	Luxembourg	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.	

Patent No.	National Patent No.	Country	Title
1171110	2219102	Spain	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
1171110		Switzerland	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
1171110		United Kingdom	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.
6127419		USA	Phenylacetic acid compositions for treating or preventing atherosclerosis and restenosis.

AUTOIMMUNE DISEASE

Patent No.	National Patent No.	Country	Title
656484		Australia	Compositions and methods for treating autoimmune diseases.
603383	E162,714	Austria	Compositions and methods for treating autoimmune diseases.
603383		Belgium	Compositions and methods for treating autoimmune diseases.
603383		Denmark	Compositions and methods for treating autoimmune diseases.

HYPERCHOLESTEROLEMIA

Patent No.	National Patent No.	Country	Title
1206936	60112872T2	Germany	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
1048588		Hong Kong	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
1206936		United Kingdom	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.
6,987,131		USA	Phenylacetic acid compositions for treating or preventing hypercholesterolemia.

LIPOSOMAL THERAPIES

Patent No.	National Patent No.	Country	Title
2254772		Canada	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
906088		France	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
906088	69734713.3-08	Germany	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

Patent No.	National Patent No.	Country	Title
4320052		Japan	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
906088		United Kingdom	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.
6013278		USA	Liposomal Antineoplastons Therapies with Markedly Improved Antineoplastic Activity.

METHODS FOR PREPARING 3-(N-PHENYLACETYLAMINO-PIPERIDINE)-2,6-DION

Patent No.	National Patent No.	Country	Title
92391		Finland	Methods for preparing 3-(N-phenylacetyl-amino-piperidine)-2,6-dion.
1562		Kazakhstan	Compositions and methods for treating autoimmune diseases.
5474		Latvia	Compositions and methods for treating autoimmune diseases.
3518		Lithuania	Compositions and methods for treating autoimmune diseases.
26099		Philippines	Compositions and methods for treating autoimmune diseases.
163552		Poland	Compositions and methods for treating autoimmune diseases.
139204		Republic of Korea	Compositions and methods for treating autoimmune diseases.



National Patent No. **Burzynski** Country Title
CLINIC HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/) OUR CLINIC ▼ SERVICES ▼
 CLINICAL TRIALS ▼ *First, Do No Harm!* INFO ▼ CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/) 1809830 Russia Compositions and methods for treating autoimmune diseases.

(<https://www.burzynskiclinic.com>)

42331	Taiwan	Compositions and methods for treating autoimmune diseases.
15756	Ukraine	Compositions and methods for treating autoimmune diseases.
4918193	USA	Methods for treating autoimmune diseases.

NEOPLASTIC DISEASE / PURIFIED

Patent No.	National Patent No.	Country	Title
551109		Australia	Purified antineoplaston fractions and methods of treating neoplastic disease.
1188218		Canada	Purified antineoplaston fractions and methods of treating neoplastic disease.
162813		Denmark	Purified antineoplaston fractions and methods of treating neoplastic disease.
302/1989		Hong Kong	Purified antineoplaston fractions and methods of treating neoplastic disease.
65960		Israel	Purified antineoplaston fractions and methods of treating neoplastic disease.
2010265		Japan	Purified antineoplaston fractions and methods of treating neoplastic disease.
2010676		Japan	Purified antineoplaston fractions.

Patent No.	National Patent No.	Country	Title
MY102918A		Malaysia	Purified antineoplaston fractions and methods of treating neoplastic disease.
200805		New Zealand	Purified antineoplaston fractions and methods of treating neoplastic disease.
163595		Norway	Purified antineoplaston fractions and methods of treating neoplastic disease.
82/4178		SouthAfrica	Purified antineoplaston fractions and methods of treating neoplastic disease.
512894		Spain	Purified antineoplaston fractions and methods of treating neoplastic disease.
4470970		USA	Purified antineoplaston fractions and methods of treating neoplastic disease.
4558057		USA	Purified antineoplaston fractions and methods of treating neoplastic disease.
4559325		USA	Purified antineoplaston fractions and methods of treating neoplastic disease.

NEUROFIBROMATOSIS

Patent No.	National Patent No.	Country	Title
683145		Australia	Methods for treating neurofibromatosis.

(https://www.burzynskiclinic.com)

No	First, Do No Harm!	Country	Title
680756		Belgium	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
680756		Denmark	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
680756		Europe	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
680756		France	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
680756	69511453	Germany	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
680756		Greece	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
1016408		Hong Kong	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
680756		Ireland	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
680756	26583/BE/9	Italy	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

(https://www.burzynskiclinic.com)

Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

680756 Luxembourg Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

680756 Monaco Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

680756 Netherlands Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

680756 Portugal Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.


680756 Slovenia Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

95/3500 South Africa Methods for treating neurofibromatosis.

680756 Spain Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

680756 Sweden Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

680756 Switzerland Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.

		Country	Title
HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/)		OUR CLINIC ▼	SERVICES ▼
CLINICAL TRIALS ▼	First, Do No Harm!	CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)	
https://www.burzynskiclinic.com		United Kingdom	Use of a combination of antineoplastons for the manufacture of a medicament for the treatment of neurofibromatosis.
5391575		USA	Methods for treating neurofibromatosis.

PARKINSON'S DISEASE

Patent No.	National Patent No.	Country	Title
638869		Australia	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Austria	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Belgium	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Denmark	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Europe	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		France	Pharmaceutical compositions for use in treating Parkinson's disease.
500905	69114261	Germany	Pharmaceutical compositions for use in treating Parkinson's disease.
500905	3018437	Greece	Pharmaceutical compositions for use in treating Parkinson's disease.

Patent No.	National Patent No.	Country	Title
500905	19057/BE/96	Italy	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Luxembourg	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Netherlands	Pharmaceutical compositions for use in treating Parkinson's disease.
28633		Philippines	Methods for treating Parkinson's disease.
91/6977		South Africa	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Spain	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Sweden	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		Switzerland	Pharmaceutical compositions for use in treating Parkinson's disease.
500905		United Kingdom	Pharmaceutical compositions for use in treating Parkinson's disease.
5089508		USA	Methods for treating Parkinson's disease.

PHARMACEUTICAL COMPOSITION COMPRISING PHENYLACETYLGLUTAMINE, ETC.

Patent No.	National Patent No.	Country	Title
------------	---------------------	---------	-------

(https://www.burzynskiclinic.com)

No	Country	Title
69232	Austria	Pharmaceutical composition comprising 3-(phenylacetylglutamine) combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
69232	Belgium	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
1262907	Canada	3-[N-Phenylacetylaminopiperidine]-2,6-dione and Process of Synthesizing Same.
69232	Europe	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
69232	France	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.



(https://www.burzynskiclinic.com)

69232	P3273952.4	Germany	Pharmaceutical composition comprising 3-(phenylacetylglutamine) in combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
-------	------------	---------	--

69232	22434/BE/86	Italy	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
-------	-------------	-------	--

69232		Luxembourg	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
-------	--	------------	--

69232		Netherlands	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
-------	--	-------------	--

69232		Sweden	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
-------	--	--------	--

Patent No.	National Patent No.	Country	Title
69232		Switzerland	Pharmaceutical composition comprising 3-(phenylacetylglutamine) in combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.
69232		United Kingdom	Pharmaceutical composition comprising phenylacetylglutamine, a combination of this compound with phenylacetic acid or 3-(phenylacetylglutamine)-piperidine-2,6-dione, a process for isolating the latter from urine and a process for the synthesis of 3-(phenylacetylglutamine)-piperidine-2,6-dione.

SKIN

Patent No.	National Patent No.	Country	Title
197358		Austria	Topical use of 3-phenylacetylglutamine-2,6-piperidinedione for treatment of skin.
197358		Belgium	Topical use of 3-phenylacetylglutamine-2,6-piperidinedione for treatment of skin.
1262866		Canada	Topical use of 3-phenylacetylglutamine-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation.
197358		Europe	Topical use of 3-phenylacetylglutamine-2,6-piperidinedione for treatment of skin.

Patent No.	National Patent No.	Country	Title
197358		Germany	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
197358		Italy	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
1953215		Japan	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
197358		Luxembourg	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
197358		Netherlands	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
197358		Sweden	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
197358		Switzerland	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
197358		United Kingdom	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin.
4593038		USA	Topical use of 3-phenylacetyl-amino-2,6-piperidinedione for treatment of skin wrinkles and hyperpigmentation.

SYNTHESIS OF 4-PHENYLBUTYRIC ACID

Patent No.	National Patent No.	Country	Title
------------	---------------------	---------	-------

(https://www.burzynskiclinic.com)

CLINICAL TRIALS	INFO	Country	Title
2447863		Canada	Synthesis of 4-phenylbutyric acid.
ZL02810264.9		China	Synthesis of 4-phenylbutyric acid.
1404638		Europe	Synthesis of 4-phenylbutyric acid. The European patent has been validated in the following contracting countries: Belgium (BE), Cyprus (CY), Germany (DE), France (FR), United Kingdom (GB), Ireland (IE), Liechtenstein (LI), Monaco (MC), Republic of Turkey (TR).
1065996		Hong Kong	Synthesis of 4-phenylbutyric acid.
229996	P0400053	Hungary	Synthesis of 4-phenylbutyric acid.
229199		India	Synthesis of 4-phenylbutyric acid.
158914		Israel	Synthesis of 4-phenylbutyric acid.
4338401		Japan	Synthesis of 4-phenylbutyric acid.
201802	P364646	Poland	Synthesis of 4-phenylbutyric acid.
10-0905139		Republic of Korea	Synthesis of 4-phenylbutyric acid.
2297998		Russia	Synthesis of 4-phenylbutyric acid.
101088		Singapore	Synthesis of 4-phenylbutyric acid.
6372938 B1		USA	Synthesis of 4-phenylbutyric acid.

TESTING PROCEDURE TO AID DIAGNOSIS OF CANCER AND EVALUATE THE PROGRESS OF CANCER THERAPY



[HOME \(HTTPS://WWW.BURZYNSKICLINIC.COM\)](https://www.burzynskiclinic.com)
[OUR CLINIC](#)
[SERVICES](#)

[CLINICAL TRIALS](#)
[INFO](#)
[CONTACT \(HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/\)](https://www.burzynskiclinic.com/contact/)

(<https://www.burzynskiclinic.com>)

Testing procedure to aid diagnosis of cancer and evaluate the progress of cancer therapy.

TOOTHPASTE

Patent No.	National Patent No.	Country	Title
7087219		USA	Toothpaste Containing Anticancer Agents.

TREATMENT OF NEOPLASTIC DISEASE

Patent No.	National Patent No.	Country	Title
1098643		Austria	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
ZL200410061600.5		China	A composition for treating neoplastic disease and the use thereof.
1098643		Europe	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
1098643		Finland	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.

(https://www.burzynskiclinic.com)
 Phenylacetylglutamine,
 Phenylacetylglutamine, and/or
 Phenylacetate for the treatment of
 neoplastic disease.

1098643	69914084.6-8	Germany	Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the treatment of neoplastic disease.
227008		India	A Phamaceutical Composition Comprising Phenylacetylglutamine, Phenylacetylisoglutamine, and/or Phenylacetate for the Treatment of Neoplastic Disease.
509244		New Zealand	A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylglutamine.
414587		Republic of Korea	A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylglutamine.
417100		Republic of Korea	A Phamaceutical Composition Comprising Phenylacetate and Phenylacetylisoglutamine.
417101		Republic of Korea	A Pharmaceutical Composition Comprising an Aqueous Solution of Phenylacetate.

TREATMENT REGIMEN



Burzynski

HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/)

OUR CLINIC ▾

SERVICES ▾



CLINICAL TRIALS ▾ First, No No Harm!

INFO ▾

CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

(https://www.burzynskiclinic.com)

Pa	Country	Title
759278	Australia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643	Belgium	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
2336945	Canada	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
ZL99811314.X	China	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643	Denmark	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
4179	Eurasia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate. The Eurasian patent has been validated in the following contracting countries: Azerbaijan, Armenia, Belarus, Kazakhstan, Kyrgyzstan, Moldova, and The Russian Federation.



(https://www.burzynskielinic.com)


	Country	Title
1098643	Greece	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1107897.8	Hong Kong	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
ID0012068	Indonesia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
ID0013227	Indonesia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
140848	Israel	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643	Italy	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643	Latvia	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.



	Country	Title
(https://www.burzynskielinic.com) 1098643	Luxembourg	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
222968	Mexico	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643	Netherlands	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
509244	New Zealand	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
213698	Poland	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643	Portugal	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
399658	Republic of Korea	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.



(https://www.burzynskielinic.com)		Country	Title
78643		Singapore	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
2001/0622		South Africa	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643	2214866	Spain	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643		Sweden	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643		Switzerland	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
1098643		United Kingdom	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.
6258849		USA	Treatment regimen for administration of phenylacetylglutamine, phenylacetylisoglutamine, and/or phenylacetate.



[HOME \(HTTPS://WWW.BURZYNSKICLINIC.COM/\)](https://www.burzynskiclinic.com/)
[OUR CLINIC](#)
[SERVICES](#)

[CLINICAL TRIALS](#)
[INFO](#)
[CONTACT \(HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/\)](https://www.burzynskiclinic.com/contact/)

(https://www.burzynskiclinic.com)

6943192B2 USA

Title: **Method for treatment of Von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives. The Eurasian patent has been validated in the following contracting countries: Azerbaijan (AZ), Kazakhstan (KZ), and Russia (RU).**

Title: **Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.**

Title: **Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.**

Title: **Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.**

VHL


Patent No.	National Patent No.	Country	Title
12908		Eurasia	Method for treatment of Von Hippel-Lindau (VHL) disease with phenylacetyl-derivatives. The Eurasian patent has been validated in the following contracting countries: Azerbaijan (AZ), Kazakhstan (KZ), and Russia (RU).
1855665		Europe	Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.
1855665		Germany	Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.
1855665		United Kingdom	Use of phenylacetyl-derivatives for the manufacture of a medicament to treat Von Hippel-Lindau (VHL) disease.

VIRAL INFECTIONS

Patent No.	National Patent No.	Country	Title
------------	---------------------	---------	-------

601164 Austria Methods for treating viral infections
(https://www.burzynskiclinic.com)

601164		Country	Title
601164		Belgium	Methods for treating viral infections.
601164		Denmark	Methods for treating viral infections.
601164		Europe	Methods for treating viral infections.
601164		France	Methods for treating viral infections.
601164	69327642.8	Germany	Methods for treating viral infections.
601164		Greece	Methods for treating viral infections.
601164		Ireland	Methods for treating viral infections.
601164		Italy	Methods for treating viral infections.
601164		Luxembourg	Methods for treating viral infections.
601164		Monaco	Methods for treating viral infections.
601164		Netherlands	Methods for treating viral infections.
601164		Portugal	Methods for treating viral infections.


National Patent Burzynski CLINIC

[HOME \(HTTPS://WWW.BURZYNSKICLINIC.COM/\)](https://www.burzynskiclinic.com/)
[OUR CLINIC ▼](#)
[SERVICES ▼](#)

[CLINICAL TRIALS ▼](#)
[First, Do No Harm!](#)
[INFO ▼](#)
[CONTACT \(HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/\)](https://www.burzynskiclinic.com/contact/)

67344 Singapore

(https://www.burzynskiclinic.com)

No.	Country	Title
601164	Spain	Methods for treating viral infections.
601164	Sweden	Methods for treating viral infections.
601164	Switzerland	Methods for treating viral infections.
601164	United Kingdom	Methods for treating viral infections.
5244922	USA	Methods for treating viral infections.

TRADE NAME

Trade Name No.	Country	Title
Reg.No.: CDN-HY-07011055; (56); (57).	China	China Domain Name Registration Certificate. Internet Keyword: Aminocare. Valid until: 5/23/2017 China Domain Name Registration Certificate. Internet Keyword: Aminocare.cn. Valid until: 5/23/2012 China Domain Name Registration Certificate. Internet Keyword: Aminocare.com.cn. Valid until: 5/23/2012

TRADEMARKS

Trademark No.	Country	Title
---------------	---------	-------



Title

HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/))

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ First, Do No Harm!
10328784 China

CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))
Avavital in Class 5

(<https://www.burzynskiclinic.com>)

No	Country	Title
10328785	China	Atengenal in Class 5
10328787	China	Cengenal in Class 5
10328788	China	Fengenal in Class 5
46957304	China	Aminocare
4006102	Europe	Fengenal in Class 5
4006334	Europe	Avavital
4006359	Europe	Bugenal in Class 5
4006375	Europe	Lubgen Farma in Classes 39 (distribution of pharmaceutical preparation) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)
4006425	Europe	Cengenal in Class 5
4006664	Europe	Astugenal in Class 5
4006979	Europe	Atengenal in Class 5
300343377	Hong Kong	Aminocare in Class 5
302118276	Hong Kong	Avavital in Class 5
302118285	Hong Kong	Atengenal in Class 5
302118294	Hong Kong	Astugenal in Class 5
302118302	Hong Kong	Cengenal in Class 5
302118311	Hong Kong	Fengenal in Class 5



HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/)

Title

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ First, Do No Harm!
247442 Israel

CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)
Fengenal in Class 5

(<https://www.burzynskiclinic.com>)

No	Country	Title
247444	Israel	Cengenal in Class 5
247445	Israel	Astugenal in Class 5 - ONLY EMAIL, NO ORIGINAL
247446	Israel	Atengenal in Class 5
247447	Israel	Avavital in Class 5
41914	Kazakhstan	Fengenal in Class 5
41913	Kazakhstan	Astugenal in Class 5
41912	Kazakhstan	Atengenal in Class 5
41911	Kazakhstan	Avavital in Class 5
41910	Kazakhstan	Fengenal in Class 5
41909	Kazakhstan	Aminocare in Class 5
67271	Lithuania	Fengenal in Class 5
67272	Lithuania	Cengenal in Class 5
67273	Lithuania	Astugenal in Class 5
67274	Lithuania	Atengenal in Class 5
67562	Lithuania	Avavital in Class 5
67275	Lithuania	Aminocare in Class 5
N/062073	Macau	Fengenal in Class 5
N/062074	Macau	Cengenal in Class 5



HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/))

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ First, Do No Harm!
N/062075 Macau

CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))
Astugenal in Class 5

(<https://www.burzynskiclinic.com>)

N/062076	Macau	Atengenal in Class 5
N/062077	Macau	Avavital in Class 5
N/062078	Macau	Aminocare in Class 5
2012054846	Malaysia	Fengenal in Class 5
2012054860	Malaysia	Cengenal in Class 5
2012054844	Malaysia	Avavital in Class 5
2012054843	Malaysia	Atengenal in Class 5
2012054850	Malaysia	Astugenal in Class 5
1598.40.01	Philippines	Fengenal in Class 5
1598.40.02	Philippines	Cengenal in Class 5
1598.40.03	Philippines	Astugenal in Class 5
1598.40.04	Philippines	Atengenal in Class 5
1598.40.05	Philippines	Avavital in Class 5
1598.40.06	Philippines	Aminocare in Class 5
188750	Poland	Lubgen Farma
120234	Republic of Korea	Lubgen Farma in Class 35 (Arranging of pharmaceutical sales)
129501	Republic of Korea	Lubgen Farma in Class 40 (custom manufacturing of pharmaceutical preparations for others)



HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/))

Title

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ First, Do No Harm!

CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))

(<https://www.burzynskiclinic.com>)

No	Country	Title
622094	Republic of Korea	Astugenal in Class 5
622095	Republic of Korea	Atengenal in Class 5
622096	Republic of Korea	Avavital in Class 5
622097	Republic of Korea	Cengenal in Class 5
622098	Republic of Korea	Fengenal in Class 5
292206	Russia	Astugenal in Class 5
293368	Russia	Bugenal in Class 5
300114	Russia	Cengenal in Class 5
304514	Russia	Lubgen Farma in Class 35 (Arranging of pharmaceutical sales) and in Class 40 (custom manufacturing of pharmaceutical preparations for others)
304679	Russia	Avavital in Class 5
304680	Russia	Atengenal in Class 5
304681	Russia	Fengenal in Class 5
327323	Russia	Aminocare in Class 5
1165897	Taiwan	Aminocare in Class 5



HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/)

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ First, Do No Harm!

CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

(https://www.burzynskiclinic.com)

No	Title	
1543739	Fengenal in Class 5	Taiwan
1543740	Cengenal in Class 5	Taiwan
1543741	Astugenal in Class 5	Taiwan
1543742	Atengenal in Class 5	Taiwan
1543743	Avavital in Class 5	Taiwan
853930	Fengenal in Class 5	Thailand
853931	Cengenal in Class 5	Thailand
853932	Astugenal in Class 5	Thailand
853933	Atengenal in Class 5	Thailand
50590	State Trademark 'Antineoplaston' - Texas	USA
1719793	Federal trademark 'Antineoplaston' for pharmaceuticals.	USA
2999213	Bugenal in Class 5	USA
3142996	Ampolgen Pharmaceuticals, LLC. In Classes 35 and 42.	USA
3160376	Aminocare in Class 6	USA
3169436	Avavital in Class 5	USA
3174860	Fengenal in Class 5	USA
3177785	Astugenal in Class 5	USA
318432	Atengenal in Class 5	USA
3276180	Cengenal in Class 5	USA



HOME (HTTPS://WWW.BURZYNSKICLINIC.COM/)

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ **First, Do No Harm!**

INFO ▼

CONTACT (HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/)

(https://www.burzynskiclinic.com)

No	Country	Title
200989	Vietnam	Cengenal in Class 5
200990	Vietnam	Astugenal in Class 5
200991	Vietnam	Atengenal in Class 5
200992	Vietnam	Avavital in Class 5
205522	Vietnam	Fengenal in Class 5

BURZYNSKI CLINIC

☎ (tel:(713) 335-5697) (713) 335-5697 (tel:(713) 335-5697)

✉ (mailto:info@burzynskiclinic.com) info@burzynskiclinic.com (mailto:info@burzynskiclinic.com)

🌐 <http://burzynskiclinic.com/> (<http://burzynskiclinic.com/>)


📍 (<https://www.google.com/maps/place/https://www.google.com/maps/place/Burzynski+Clinic>

[/@29.7864766,-95.5273116,17z](https://www.google.com/maps/place/https://www.google.com/maps/place/Burzynski+Clinic/@29.7864766,-95.5273116,17z)
/data=!3m1!4b1!4m5!3m4!1s0x8640c48c7edce837:0x4def17e272780d39!8m2!3d29.786472!4d-95.5251229) 9432 Katy Freeway, Houston, Texas 77055 (<https://www.google.com/maps/place/https://www.google.com/maps/place/Burzynski+Clinic/@29.7864766,-95.5273116,17z>
/data=!3m1!4b1!4m5!3m4!1s0x8640c48c7edce837:0x4def17e272780d39!8m2!3d29.786472!4d-95.5251229)

USEFUL RESOURCES

Privacy Policy (<https://burzynskiclinic.com/privacy-policy/>)

Primary Care Physician Houston (<https://www.houstonconcierngemedicine.com/>)



HOME ([HTTPS://WWW.BURZYNSKICLINIC.COM/](https://www.burzynskiclinic.com/))

OUR CLINIC ▼

SERVICES ▼



CLINICAL TRIALS ▼ *First, Do No Harm!*

INFO ▼

CONTACT ([HTTPS://WWW.BURZYNSKICLINIC.COM/CONTACT/](https://www.burzynskiclinic.com/contact/))

(<https://www.burzynskiclinic.com>)

Copyright ©2023 All Rights Reserved